

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
11 November 2004 (11.11.2004)

PCT

(10) International Publication Number
WO 2004/096128 A2

(51) International Patent Classification⁷: **A61K**
(21) International Application Number:
PCT/US2004/011759

GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 16 April 2004 (16.04.2004)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
60/465,176 24 April 2003 (24.04.2003) US

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

(71) Applicant (for all designated States except US): **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 and Province Line Road, Princeton, NJ 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **NAIDU, B. Narasimhulu** [IN/US]; 12 Skeetfield Point Rd., Durham, CT 06422 (US). **WALKER, Michael, A.** [US/US]; 76R Ivy Way, Durham, CT 06422 (US). **SORENSEN, Margaret, E.** [US/US]; 27 Harrison Street, Apt. 13, Meriden, CT 06450 (US).

(74) Agents: **EPPELSON, James et al.**; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,


— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **HIV INTEGRASE INHIBITORS**



(57) Abstract: The present invention relates to a series of pyrimidine compounds of Formula (I) which inhibit HIV integrase and to pharmaceutical compositions and methods of treatment for AIDS or ARC using these compounds.

WO 2004/096128 A2

HIV INTEGRASE INHIBITORS

CROSS-REFERENCE TO RELATED APPLICATIONS

5

This application claims the benefit of US provisional application 60/465,176, filed April 24, 2003.

BACKGROUND OF THE INVENTION

10

HIV expresses three enzymes, reverse transcriptase, an aspartyl protease and integrase, all of which are potential antiviral targets for the development of drugs for the treatment of AIDS. However, integrase stands out as being the only viral enzyme not targeted by current therapy. The integrase enzyme is responsible for insertion of the viral cDNA into the host cell genome, which is a critical step in the viral life cycle. There are a number of discrete steps involved in this process including processing of the viral cDNA by removal of two bases from each 3'-terminus and joining of the recessed ends to the host DNA. Studies have shown that in the absence of a functional integrase enzyme HIV is not infectious. (Lafemina, R. L.; Schneider, C. L.; Robbins, H. L.; Callahan, P. L.; LeGrow, K.; Roth, E.; Emini, E. A. *J. Virol.* 1992, 66, 7414-7419 and Englund, G.; Theodore, T. S.; Freed, E.; Engelman, A.; Martin, M. A. *J. Virol.* 1995, 69, 3216-3219) Therefore, an inhibitor of integrase would be useful as a therapy for AIDS and HIV infection.

25

Human immunodeficiency virus (HIV) has been identified as the etiological agent responsible for acquired immune deficiency syndrome (AIDS), a fatal disease characterized by destruction of the immune system and the inability to fight off life threatening opportunistic infections. Recent statistics (UNAIDS: Report on the Global HIV/AIDS Epidemic, December 1998), indicate that as many as 33 million people worldwide are infected with the virus. In addition to the large number of individuals already infected, the virus continues to spread. Estimates from 1998 point to close to 6 million new infections in that year alone. In the same year there were approximately 2.5 million deaths associated with HIV and AIDS.

30

There are currently a number of antiviral drugs available to combat the infection. These drugs can be divided into three classes based on the viral protein they target and their mode of action. In particular, saquinavir, indinavir, ritonavir, nelfinavir and amprenavir are competitive inhibitors of the aspartyl protease expressed by HIV. Zidovudine, didanosine, stavudine, lamivudine, zalcitabine and abacavir are nucleoside reverse transcriptase inhibitors that behave as substrate mimics to halt viral cDNA synthesis. The non-nucleoside reverse transcriptase inhibitors, nevirapine, delavirdine and efavirenz inhibit the synthesis of viral cDNA via a non-competitive (or uncompetitive) mechanism. Used alone these drugs are effective in reducing viral replication. The effect is only temporary as the virus readily develops resistance to all known agents. However, combination therapy has proven very effective at both reducing virus and suppressing the emergence of resistance in a number of patients. In the US, where combination therapy is widely available, the number of HIV-related deaths has declined (Palella, F. J.; Delany, K. M.; Moorman, A. C.; Loveless, M. O.; Furher, J.; Satten, G. A.; Aschman, D. J.; Holmberg, S. D. *N. Engl. J. Med.* 1998, 338, 853-860).

Unfortunately, not all patients are responsive and a large number fail this therapy. In fact, approximately 30-50% of patients ultimately fail combination therapy. Treatment failure in most cases is caused by the emergence of viral resistance. Viral resistance in turn is caused by the rapid turnover of HIV-1 during the course of infection combined with a high viral mutation rate. Under these circumstances incomplete viral suppression caused by insufficient drug potency, poor compliance to the complicated drug regiment as well as intrinsic pharmacological barriers to exposure provides fertile ground for resistance to emerge. More disturbing are recent findings which suggest that low-level replication continues even when viral plasma levels have dropped below detectable levels (< 50 copies/ml) (Carpenter, C. C.; Cooper, D. A.; Fischl, M. A.; Gatell, J. M.; Gazzard, B. G.; Hammer, S. M.; Hirsch, M. S.; Jacobsen, D. M.; Katzenstein, D. A.; Montaner, J. S.; Richman, D. D.; Saag, M. S.; Schechter, M.; Schooley, R. T.; Thompson, M. A.; Vella, S.; Yeni, P. G.; Volberding, P. A. *JAMA* 2000, 283, 381-390). Clearly there is a need for new antiviral agents, preferably targeting other viral enzymes to reduce the rate of resistance and suppress viral replication even further.


A number of HIV integrase inhibitors have been reported. These include nucleotide-based inhibitors, known DNA binders, catechols and hydrazide containing derivatives (Neamati, N.; Sunder, S.; Pommier, Y., *Drug Disc. Today*, 1997, 2, 487).

5 Certain pyrimidines and pyrimidinones have been disclosed. WO 02/06246 discloses 2-aryl-4,5-dihydroxy-6-carboxypyrimidines as viral polymerase inhibitors which are proposed for use in treating hepatitis C virus infection. Sunderland, C. J; Botta, M.; Aime, S.; and Raymond, K. N. *Inorg. Chem.* (2001) 40, 6746-6756 discloses the synthesis of 6-carboxamido-5,4-hydroxypyrimidinones as gadolinium
10 chelating agents. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV. Nothing in these references teaches or suggests the novel compounds of this invention or their use as HIV integrase inhibitors.

15

SUMMARY OF INVENTION


The invention encompasses a series of compounds of structural Formula I which inhibit HIV integrase. This action makes the compounds useful for treating
20 HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.



25

DETAILED DESCRIPTION OF THE INVENTION

The invention comprises compounds of Formula I, including pharmaceutically acceptable salts and solvates, their pharmaceutical compositions, and their use in preventing HIV attachment and treating those infected with HIV.
30 The compounds of Formula I are described with the following meanings:




wherein

A is methylene or 1,1-disubstituted ethylene;

5

B is selected from the group consisting of



- 10 R^1 is phenyl, pyridinyl or dioxolanylphenyl and is unsubstituted or substituted with 1 to 3 R^3 ;

R^2 is hydrogen, methyl, or OR^4 ;

- 15 R^3 is independently selected from halo, C_{1-6} alkyl, C_{1-2} perfluoroalkyl, C_{1-6} alkoxy, C_{1-6} alkylthioxy, and cyano;

R^4 is hydrogen or C_{1-6} alkyl;

- 20 R^5 is Ar^1 or Ar^2 ;

R^6 is C_{1-6} alkyl;

- 25 Ar^1 is phenyl unsubstituted or substituted with 1-2 substituents selected from halo, C_{1-6} alkoxy, CO_2R^4 , $\text{N}(\text{R}^4)(\text{SO}_2\text{C}_{1-6}\text{alkyl})$, $\text{SO}_2\text{N}(\text{C}_{1-6}\text{alkyl})_2$, and dioxothiazinanyl;

Ar^2 is a heteroaryl moiety selected from the group consisting of pyridinyl, pyrrolyl, furanyl, and imidazopyrimidinyl and is unsubstituted or substituted with 1-2

substituents selected from halo, C₁₋₆alkyl, C₁₋₆alkoxy, CO₂R⁴, N(R⁴)(SO₂C₁₋₆alkyl), SO₂N(C₁₋₆alkyl)₂, N(R⁷)₂, and dioxothiazinanyl;

R⁷ is hydrogen, C₁₋₆alkyl, C₁₋₆alkylOR⁴.

5

One aspect of the invention are compounds of Formula I wherein R¹ is phenyl unsubstituted or substituted with 1 to 3 R³.

Another aspect of the invention are compounds of Formula I where R¹ is
10 phenyl substituted with 1-2 R³ selected from the group consisting of chloro, fluoro, methyl, and trifluoromethyl.

Another aspect of the invention are compounds of Formula I where R² is hydrogen.

15

Another aspect of the invention are compounds of Formula I where R⁵ is Ar¹.

Another aspect of the invention are compounds of Formula I where Ar¹ is
20 phenyl substituted with 1-2 R³ selected from the group consisting of chloro, fluoro, methoxy, N(Me)SO₂Me, SO₂N(Me)₂, SO₂Me, and dioxothiazinanyl.

Another aspect of the invention are compounds of Formula I where R⁵ is Ar².

Another aspect of the invention are compounds of Formula I where Ar² is
25 substituted with 1-2 substituents selected from the group consisting of chloro, fluoro, methyl, methoxy, dimethylamino, 2-hydroxyethylamino, di(2-hydroxyethyl)amino, N(Me)SO₂Me, SO₂N(Me)₂, SO₂Me, and dioxothiazinanyl.

Another aspect of the invention are compounds of Formula I where R⁶ is
30 methyl.

Some compounds of the invention are

N-(4-fluorobenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

5 N-(3,4-dichlorobenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-difluorobenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

10 N-(4-chlorobenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(4-methylbenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

15

N-(3,4-dimethylbenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

20 N-(3-chloro-4-methylbenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(2,4-difluorobenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

25 N-(2-methylbenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(4-fluoro-2-(trifluoromethyl)benzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

30

N-(4-(trifluoromethyl)benzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(benzo[d][1,3]dioxol-5-ylmethyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-N-(1-phenylethyl)-1,6-
5 dihydropyrimidine-4-carboxamide;

N-(2-(methylthio)benzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

10 N-(3-fluoro-4-(trifluoromethyl)benzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3,5-bis(trifluoromethyl)benzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

15 2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-N-(pyridin-2-ylmethyl)-1,6-dihydropyrimidine-4-carboxamide;

N-benzyl-5-hydroxy-1-methyl-6-oxo-2-phenyl-1,6-dihydropyrimidine-4-
20 carboxamide;

N-(4-chlorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-2-yl)-1,6-dihydropyrimidine-4-carboxamide;

25 N-(3,4-dichlorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-2-yl)-1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-difluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-2-yl)-1,6-dihydropyrimidine-4-carboxamide;

30 N-(4-methylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-2-yl)-1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-dimethylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-2-yl)-1,6-dihydropyrimidine-4-carboxamide;

5 N-(3-chloro-4-methylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-2-yl)-1,6-dihydropyrimidine-4-carboxamide;

N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-2-yl)-1,6-dihydropyrimidine-4-carboxamide;

10 N-(3,4-dichlorobenzyl)-5-hydroxy-2-(2-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(4-fluorobenzyl)-5-hydroxy-2-(2-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

15 N-(3,4-dimethylbenzyl)-5-hydroxy-2-(2-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

20 N-(3-chloro-4-methylbenzyl)-5-hydroxy-2-(2-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(4-fluorobenzyl)-2-(4-fluoro-2-(methylsulfonyl)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

25 N-(3,4-dichlorobenzyl)-2-(4-fluoro-2-(methylsulfonyl)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-dimethylbenzyl)-2-(4-fluoro-2-(methylsulfonyl)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

30 N-(4-fluorobenzyl)-2-(2-fluoro-6-(N-methylmethan-3-ylsulfonamido)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

- N-(3,4-dichlorobenzyl)-2-(2-fluoro-6-(N-methylmethan-3-ylsulfonamido)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- 5 N-(3-chloro-4-methylbenzyl)-2-(2-fluoro-6-(N-methylmethan-3-ylsulfonamido)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- 10 N-(4-fluorobenzyl)-2-(2,6-dimethoxyphenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- 15 N-(3,4-dichlorobenzyl)-2-(2,6-dimethoxyphenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- N-(3,4-dimethylbenzyl)-2-(2,6-dimethoxyphenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- 20 N-(3-chloro-4-methylbenzyl)-2-(2,6-dimethoxyphenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(2-(1,1-Dioxo-1 λ^6 -[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- 25 N-(3,4-dichlorobenzyl)-5-hydroxy-1-methyl-2-(2-(1,1-Dioxo-1 λ^6 -[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- N-(3,4-dimethylbenzyl)-5-hydroxy-1-methyl-2-(2-(1,1-Dioxo-1 λ^6 -[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- 30 N-(3-chloro-4-methylbenzyl)-5-hydroxy-1-methyl-2-(2-(1,1-Dioxo-1 λ^6 -[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(2-morpholinophenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

5 N-(3,4-dichlorobenzyl)-5-hydroxy-1-methyl-2-(2-morpholinophenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-dimethylbenzyl)-5-hydroxy-1-methyl-2-(2-morpholinophenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

10 N-(3-chloro-4-methylbenzyl)-5-hydroxy-1-methyl-2-(2-morpholinophenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(4-fluorobenzyl)-2-(2-dimethylsulfamoylphenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

15

N-(3,4-dichlorobenzyl)-2-(2-dimethylsulfamoylphenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

20 N-(3,4-dimethylbenzyl)-2-(2-dimethylsulfamoylphenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3-chloro-4-methylbenzyl)-2-(2-dimethylsulfamoylphenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

25 N-(4-fluorobenzyl)-5-hydroxy-2-(3-[2-(1,1-Dioxo-1 λ ⁶-[1,2]thiazinan-2-yl)-pyridin-2-yl]-)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-dichlorobenzyl)-5-hydroxy-2-(3-[2-(1,1-Dioxo-1 λ ⁶-[1,2]thiazinan-2-yl)-pyridin-2-yl]-)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

30

N-(3,4-dimethylbenzyl)-5-hydroxy-2-(3-[2-(1,1-Dioxo-1 λ ⁶-[1,2]thiazinan-2-yl)-pyridin-2-yl]-)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3-chloro-4-methylbenzyl)-5-hydroxy-2-(3-[2-(1,1-Dioxo-1 λ ⁶-[1,2]thiazinan-2-yl)-pyridin-2-yl])-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

5 N-(4-fluorobenzyl)-5-hydroxy-2-(6-methoxypyridin-3-yl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-dichlorobenzyl)-5-hydroxy-2-(6-methoxypyridin-3-yl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

10 N-(3,4-dimethylbenzyl)-5-hydroxy-2-(6-methoxypyridin-3-yl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(4-fluorobenzyl)-5-hydroxy-2-(3-methoxypyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

15 N-(4-fluorobenzyl)-2-(3-(dimethylamino)pyridin-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

20 N-(3,4-dichlorobenzyl)-2-(3-(dimethylamino)pyridin-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-dimethylbenzyl)-2-(3-(dimethylamino)pyridin-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

25 N-(3-chloro-4-methylbenzyl)-2-(3-(dimethylamino)pyridin-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-phenyl-1,6-dihydropyrimidine-4-carboxamide;

30 N-(3,4-dichlorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-phenyl-1,6-dihydropyrimidine-4-carboxamide;

- N-(3,4-dimethylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-phenyl-1,6-dihydropyrimidine-4-carboxamide;
- 5 N-(3-chloro-4-methylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-phenyl-1,6-dihydropyrimidine-4-carboxamide;
- N-(4-fluorobenzyl)-5-hydroxy-2-(3-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- 10 N-(3,4-dichlorobenzyl)-5-hydroxy-2-(3-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- N-(3,4-dimethylbenzyl)-5-hydroxy-2-(3-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- 15 N-(4-fluorobenzyl)-5-hydroxy-2-(4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- N-(3,4-dichlorobenzyl)-5-hydroxy-2-(4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- 20 N-(3,4-dimethylbenzyl)-5-hydroxy-2-(4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- 25 N-(4-fluorobenzyl)-5-hydroxy-2-[2-(2-hydroxyethylamino)phenyl]-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylate;
- N-(3,4-dichlorobenzyl)-5-hydroxy-2-[2-(2-hydroxyethylamino)phenyl]-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylate;
- 30 N-(4-fluorobenzyl)-2-(2-(bis(2-hydroxyethyl)amino)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

2-(4-((4-fluorobenzyl)carbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)benzoic acid;

2-(4-((3,4-dichlorobenzyl)carbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-
5 dihydropyrimidin-2-yl)benzoic acid;

N-(4-fluorobenzyl)-2-(2-(dimethylamino)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

10 N-(3,4-dichlorobenzyl)-2-(2-(dimethylamino)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-dimethylbenzyl)-2-(2-(dimethylamino)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

15

N-(3-chloro-4-methylbenzyl)-2-(2-(dimethylamino)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

20 N-(4-fluorobenzyl)-2-(furan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-dichlorobenzyl)-2-(furan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

25 N-(3,4-dimethylbenzyl)-2-(furan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3-chloro-4-methylbenzyl)-2-(furan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

30

N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-3-yl)-1,6-dihydropyrimidine-4-carboxamide;

- N-(3,4-dichlorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-3-yl)-1,6-dihydropyrimidine-4-carboxamide;
- 5 N-(3,4-dimethylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-3-yl)-1,6-dihydropyrimidine-4-carboxamide;
- N-(3-chloro-4-methylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-3-yl)-1,6-dihydropyrimidine-4-carboxamide;
- 10 N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-4-yl)-1,6-dihydropyrimidine-4-carboxamide;
- N-(3,4-dichlorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-4-yl)-1,6-dihydropyrimidine-4-carboxamide;
- 15 N-(3,4-dimethylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-4-yl)-1,6-dihydropyrimidine-4-carboxamide;
- N-(3-chloro-4-methylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-4-yl)-1,6-dihydropyrimidine-4-carboxamide;
- 20 N-(4-fluorobenzyl)-2-(1,5-dimethyl-1H-pyrrol-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- N-(3,4-dichlorobenzyl)-2-(1,5-dimethyl-1H-pyrrol-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- 25 N-(3,4-dimethylbenzyl)-2-(1,5-dimethyl-1H-pyrrol-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- 30 N-(3-chloro-4-methylbenzyl)-2-(1,5-dimethyl-1H-pyrrol-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(4-fluorobenzyl)-2-(2,4-dimethylimidazo[1,5-a]pyrimidin-8-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

5 N-(3,4-dichlorobenzyl)-2-(2,4-dimethylimidazo[1,5-a]pyrimidin-8-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-methylbenzyl)-2-(2,4-dimethylimidazo[1,5-a]pyrimidin-8-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide

10 N-(3-chloro-4-methylbenzyl)-2-(2,4-dimethylimidazo[1,5-a]pyrimidin-8-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide.

2-(4-methylaminocarbonyl-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid 4-fluorobenzylamide; and

15

N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-p-tolyl-1,6-dihydropyrimidine-4-carboxamide;

20 “Alkyl” and “alkoxy” includes straight and branched saturated hydrocarbon substituents. “Aryl” includes carbocyclic and heterocyclic aromatic substituents.

The invention includes all pharmaceutically acceptable salt forms of the compounds. Pharmaceutically acceptable salts are those in which the counter ions do not contribute significantly to the physiological activity or toxicity of the compounds and as such function as pharmacological equivalents. These salts can be made according to common organic techniques employing commercially available reagents. Some anionic salt forms include acetate, acistrate, besylate, bromide, chloride, citrate, fumarate, glucouronate, hydrobromide, hydrochloride, hydroiodide, iodide, lactate, maleate, mesylate, nitrate, pamoate, phosphate, succinate, sulfate, tartrate, tosylate, and xinofoate. Some cationic salt forms include ammonium, aluminum, benzathine, bismuth, calcium, choline, diethylamine, diethanolamine, lithium, magnesium, meglumine, 4-phenylcyclohexylamine, piperazine, potassium, sodium, tromethamine, and zinc.


25

30

The invention also includes all solvated forms of the compounds, particularly hydrates. Solvates do not contribute significantly to the physiological activity or toxicity of the compounds and as such function as pharmacological equivalents. Solvates may form in stoichiometric amounts or may form from adventitious solvent or a combination of both. One type of solvate is hydrate, and some hydrated forms include monohydrate, hemihydrate, and dihydrate.

Certain compounds of Formula I may contain one or more chiral centers and exist in different optically active forms. When compounds of Formula I contain one chiral center, the compounds exist in two enantiomeric forms. The present invention includes both enantiomers and mixtures of enantiomers such as racemic mixtures. The enantiomers may be resolved by methods known in the art. Alternatively, specific enantiomers may be synthesized by asymmetric synthesis using reactions known in the art.

The compounds of this invention can also exist as tautomers, as shown below; therefore the present invention also includes all tautomeric forms.




Synthetic Methods

General methods useful for the synthesis of the compounds of this invention are shown below. Related compounds can be made by reactions known in the art.

Synthetic methods for the preparation of pyrimidines similar to those described in the current invention have been published (Gardelli, C. et al PCT Appl. WO 02/06246). The compounds of the present invention can be synthesized according to Scheme I. In Scheme I, aryl nitrile **I-1** is reacted with N-hydroxylamine **I-2**. The intermediate **I-3** generated from this reaction can be isolated but more often

is reacted in one pot with dialkyl acetylenedicarboxylate **I-4** to yield the diesters **1-5a** or **I-5b**. The diesters **1-5a** or **I-5b** were converted to pyrimidine carboxylate **I-6** by heating at or above 120 °C in an appropriate solvent. The ester **I-6** is condensed with amine **I-7** to give the amide **I-8**. The amide coupling reaction can be carried out under a variety of conditions such as those disclosed in Jerry March, Advanced Organic Chemistry, 3rd edition, John Wiley & Sons, 1985.


Scheme I



In Scheme II, an alternative pathway is shown in which the R⁶ group is introduced at a later stage of the synthesis. Synthetic methods for the preparation of pyrimidines similar to those described in the current invention have been published (Sunderland, J. S.; et al. Inorg. Chem. (2001), 40, 6756-6756). The compounds of the present invention can be synthesized according to Scheme II. In Scheme II, an oxalic acid diester **II-1** is condensed with glycolate **II-2** using sodium hydride or a similar base. The intermediate **II-3** generated from this reaction can be isolated but more often is reacted in one pot with an appropriately substituted amidine **II-4** to

yield the pyrimidinone heterocycle **II-5**. Intermediate **II-5** is coupled with amine **II-6**. Alternatively, the pyrimidinone **II-5** is alkylated with a suitable electrophile under basic conditions. Then intermediate **II-9** is coupled with amine **II-6**. The amides, **II-8** and **II-10** are then treated under conditions appropriate for cleaving the protecting group P. For alkyl groups, where P is alkyl, this can be accomplished by BBr_3 or other conditions known in the art. Alternatively, when P is a benzylic or substituted benzylic group the ether can be cleaved under reductive conditions, oxidative conditions or acidic conditions. Protecting groups, R, useful for the synthesis of compounds such as 1-9 can be found in Greene, T. W. and Wutz, P. G. M. Protective Groups in Organic Synthesis, Second Edition, 1991, John Wiley and Sons, New York.

Scheme II



Pharmaceutical Compositions and Methods of Treatment

The compounds of this invention inhibit HIV integrase. HIV integrase inhibitors belonging to a class of diketo acid compounds prevented viral integration and inhibited HIV-1 replication in cells (Hazuda et al. Science 2000, 287, 646).
5 Recently, HIV integrase inhibitors have been accepted into clinical trials for treating AIDS and HIV infection (Neamati Expert. Opin. Ther. Patents 2002, 12, 709, Pais and Burke Drugs Fut. 2002, 27, 1101).

10 Accordingly, another aspect of the invention is a method for treating HIV infection in a human patient comprising administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, with a pharmaceutically acceptable carrier.

15 Another aspect of the invention is a method for treating HIV infection in a human patient comprising administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, with a therapeutically effective amount of at least one other agent used for treatment of AIDS or HIV infection. Some suitable agents are nucleoside HIV reverse
20 transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors.

25 Another aspect of the invention is a composition for treating HIV infection in a human patient comprising administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, with a pharmaceutically acceptable carrier.

30

“Combination,” “coadministration,” “concurrent,” and similar terms referring to the administration of compounds of Formula I with at least one anti-HIV agent mean that the components are part of a combination antiretroviral therapy or highly active antiretroviral therapy (HAART) as understood by practitioners in the field of
5 AIDS and HIV infection.

“Therapeutically effective” means the amount of agent required to provide a meaningful patient benefit as understood by practitioners in the field of AIDS and HIV infection. In general, the goals of treatment are suppression of viral load,
10 restoration and preservation of immunologic function, improved quality of life, and reduction of HIV-related morbidity and mortality.

“Patient” means a person infected with the HIV virus and suitable for therapy as understood by practitioners in the field of AIDS and HIV infection.
15

“Treatment,” “therapy,” “regimen,” “HIV infection,” “ARC,” “AIDS” and related terms are used as understood by practitioners in the field of AIDS and HIV infection.

20 The compounds of this invention are generally given as pharmaceutical compositions comprised of a therapeutically effective amount of a compound of Formula I or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier and may contain conventional excipients. A therapeutically effective amount is that which is needed to provide a meaningful patient benefit. Pharmaceutically
25 acceptable carriers are those conventionally known carriers having acceptable safety profiles. Compositions encompass all common solid and liquid forms including capsules, tablets, lozenges, and powders as well as liquid suspensions, syrups, elixers, and solutions. Compositions are made using common formulation techniques, and conventional excipients (such as binding and wetting agents) and vehicles (such as
30 water and alcohols) are generally used for compositions.

Solid compositions are normally formulated in dosage units and compositions providing from about 1 to 1000 mg of the active ingredient per dose are preferred.

Some examples of dosages are 1 mg, 10, mg, 100, mg, 250 mg, 500 mg, and 1000 mg. Generally, other antiretroviral agents will be present in a unit range similar to agents of that class used clinically. Typically, this 0.25-1000 mg/unit.

5 Liquid compositions are usually in dosage unit ranges. Generally, the liquid composition will be in a unit dosage range of 1-100 mg/mL. Some examples of dosages are 1 mg/mL, 10 mg/mL, 25, mg/mL, 50 mg/mL, and 100 mg/mL. Generally, other antiretroviral agents will be present in a unit range similar to agents of that class used clinically. Typically, this is 1-100 mg/mL.

10

 The invention encompasses all conventional modes of administration; oral and parenteral methods are preferred. Generally, the dosing regimen will be similar to other antiretroviral agents used clinically. Typically, the daily dose will be 1-100 mg/kg body weight daily. Generally, more compound is required orally and less
15 parenterally. The specific dosing regime, however, will be determined by a physician using sound medical judgement.

 The invention also encompasses methods where the compound is given in combination therapy. That is, the compound can be used in conjunction with, but
20 separately from, other agents useful in treating AIDS and HIV infection. Some of these agents include HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV cell fusion inhibitors, HIV integrase inhibitors, HIV nucleoside reverse transcriptase inhibitors, HIV non-nucleoside reverse transcriptase inhibitors, HIV protease inhibitors, budding and maturation inhibitors, immunomodulators, and anti-
25 infectives. In these combination methods, Compound 1 will generally be given in a daily dose of 1-100 mg/kg body weight daily in conjunction with other agents. The other agents generally will be given in the amounts used therapeutically. The specific dosing regime, however, will be determined by a physician using sound medical judgement.

30

Table 1 lists some agents useful in treating AIDS and HIV infection which are suitable for this invention.

Table 1. ANTIVIRALS

Drug Name	Manufacturer	Indication
097 (non-nucleoside reverse transcriptase inhibitor)	Hoechst/Bayer	HIV infection, AIDS, ARC
Amprenavir 141 W94 GW 141 (protease inhibitor)	Glaxo Wellcome	HIV infection, AIDS, ARC
Abacavir (1592U89) GW 1592 (RT inhibitor)	Glaxo Wellcome	HIV infection, AIDS, ARC
Acemannan	Carrington Labs (Irving, TX)	ARC
Acyclovir	Burroughs Wellcome	HIV infection, AIDS, ARC, in combination with AZT
AD-439	Tanox Biosystems	HIV infection, AIDS, ARC
AD-519	Tanox Biosystems	HIV infection, AIDS, ARC
Adefovir dipivoxil AL-721	Gilead Sciences Ethigen (Los Angeles, CA)	HIV infection, ARC, PGL HIV positive, AIDS
Alpha Interferon HIV in combination w/Retrovir	Glaxo Wellcome	Kaposi's sarcoma
Ansamycin LM 427	Adria Laboratories (Dublin, OH) Erbamont (Stamford, CT)	ARC
Antibody which Neutralizes pH Labile alpha aberrant Interferon	Advanced Biotherapy Concepts (Rockville, MD)	AIDS, ARC
AR177	Aronex Pharm	HIV infection, AIDS, ARC
Beta-fluoro-ddA	Nat'l Cancer Institute	AIDS-associated diseases
BMS-232623 (CGP-73547) (protease inhibitor)	Bristol-Myers Squibb/ Novartis	HIV infection, AIDS, ARC
BMS-234475 (CGP-61755) (protease inhibitor)	Bristol-Myers Squibb/ Novartis	HIV infection, AIDS, ARC
CI-1012	Warner-Lambert	HIV-1 infection

Drug Name	Manufacturer	Indication
Cidofovir	Gilead Science	CMV retinitis, herpes, papillomavirus
Curdlan sulfate	AJI Pharma USA	HIV infection
Cytomegalovirus Immune globin	MedImmune	CMV retinitis
Cytovene	Syntex	Sight threatening
Ganciclovir		CMV peripheral, CMV retinitis
Delaviridine (RT inhibitor)	Pharmacia-Upjohn	HIV infection, AIDS, ARC
Dextran Sulfate	Ueno Fine Chem. Ind. Ltd. (Osaka, Japan)	AIDS, ARC, HIV positive asymptomatic
ddC Dideoxycytidine	Hoffman-La Roche	HIV infection, AIDS, ARC
ddI Dideoxyinosine	Bristol-Myers Squibb	HIV infection, AIDS, ARC; combination with AZT/d4T
DMP-450 (protease inhibitor)	AVID (Camden, NJ)	HIV infection, AIDS, ARC
Efavirenz (DMP 266) (-)-6-Chloro-4-(S)-cyclopropylethynyl-4(S)-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one, STOCRINE (non-nucleoside RT inhibitor)	DuPont Merck	HIV infection, AIDS, ARC
EL10	Elan Corp, PLC (Gainesville, GA)	HIV infection
Famciclovir	Smith Kline	herpes zoster, herpes simplex
FTC (reverse transcriptase inhibitor)	Emory University	HIV infection, AIDS, ARC
GS 840 (reverse transcriptase inhibitor)	Gilead	HIV infection, AIDS, ARC
HBV097 (non-nucleoside reverse transcriptase inhibitor)	Hoechst Marion Roussel	HIV infection, AIDS, ARC
Hypericin	VIMRx Pharm.	HIV infection, AIDS, ARC

Drug Name	Manufacturer	Indication
Recombinant Human Interferon Beta	Triton Biosciences (Alameda, CA)	AIDS, Kaposi's sarcoma, ARC
Interferon alfa-n3	Interferon Sciences	ARC, AIDS
Indinavir	Merck	HIV infection, AIDS, ARC, asymptomatic HIV positive, also in combination with AZT/ddI/ddC
ISIS 2922	ISIS Pharmaceuticals	CMV retinitis
KNI-272	Nat'l Cancer Institute	HIV-associated diseases
Lamivudine, 3TC (reverse transcriptase inhibitor)	Glaxo Wellcome	HIV infection, AIDS, ARC, also with AZT
Lobucavir	Bristol-Myers Squibb	CMV infection
Nelfinavir (protease inhibitor)	Agouron Pharmaceuticals	HIV infection, AIDS, ARC
Nevirapine (RT inhibitor)	Boehringer Ingelheim	HIV infection, AIDS, ARC
Novapren	Novaferon Labs, Inc. (Akron, OH)	HIV inhibitor
Peptide T Octapeptide Sequence	Peninsula Labs (Belmont, CA)	AIDS
Trisodium Phosphonoformate	Astra Pharm. Products, Inc.	CMV retinitis, HIV infection, other CMV infections
PNU-140690 (protease inhibitor)	Pharmacia Upjohn	HIV infection, AIDS, ARC
Probucol	Vyrex	HIV infection, AIDS
RBC-CD4	Sheffield Med. Tech (Houston, TX)	HIV infection, AIDS, ARC
Ritonavir (protease inhibitor)	Abbott	HIV infection, AIDS, ARC
Saquinavir (protease inhibitor)	Hoffmann-LaRoche	HIV infection, AIDS, ARC
Stavudine; d4T Didehydrodeoxy-thymidine	Bristol-Myers Squibb	HIV infection, AIDS, ARC
Valaciclovir	Glaxo Wellcome	Genital HSV & CMV infections
Virazole Ribavirin	Viratek/ICN (Costa Mesa, CA)	asymptomatic HIV-positive, LAS, ARC
VX-478	Vertex	HIV infection, AIDS, ARC
Zalcitabine	Hoffmann-LaRoche	HIV infection, AIDS, ARC, with AZT

Drug Name	Manufacturer	Indication
Zidovudine; AZT	Glaxo Wellcome	HIV infection, AIDS, ARC, Kaposi's sarcoma, in combination with other therapies
Tenofovir disoproxil, fumarate salt (Viread [®]) (reverse transcriptase inhibitor)	Gilead	HIV infection, AIDS
Combivir [®] (reverse transcriptase inhibitor)	GSK	HIV infection, AIDS
abacavir succinate (or Ziagen [®]) (reverse transcriptase inhibitor)	GSK	HIV infection, AIDS
Reyataz [®] (atazanavir)	Bristol-Myers Squibb	HIV infection, AIDS
Fuzeon (Enfuvirtide, T-20)	Roche/Trimeris	HIV infection, AIDS, viral fusion inhibitor
Trizivir [®]		HIV infection, AIDS
Kaletra [®]	Abbott	HIV infection, AIDS, ARC

IMMUNOMODULATORS

Drug Name	Manufacturer	Indication
AS-101	Wyeth-Ayerst	AIDS
Bropiramine	Pharmacia Upjohn	Advanced AIDS
Acemannan	Carrington Labs, Inc. (Irving, TX)	AIDS, ARC
CL246,738	American Cyanamid Lederle Labs	AIDS, Kaposi's sarcoma
EL10	Elan Corp, PLC (Gainesville, GA)	HIV infection
FP-21399	Fuki ImmunoPharm	Blocks HIV fusion with CD4+ cells
Gamma Interferon	Genentech	ARC, in combination w/TNF (tumor necrosis factor)
Granulocyte Macrophage Colony Stimulating Factor	Genetics Institute Sandoz	AIDS
Granulocyte Macrophage Colony Stimulating Factor	Hoechst-Roussel Immunex	AIDS

Drug Name	Manufacturer	Indication
Granulocyte Macrophage Colony Stimulating Factor	Schering-Plough	AIDS, combination w/AZT
HIV Core Particle Immunostimulant	Rorer	Seropositive HIV
IL-2 Interleukin-2	Cetus	AIDS, in combination w/AZT
IL-2 Interleukin-2	Hoffman-LaRoche Immunex	AIDS, ARC, HIV, in combination w/AZT
IL-2 Interleukin-2 (aldeslukin)	Chiron	AIDS, increase in CD4 cell counts
Immune Globulin Intravenous (human)	Cutter Biological (Berkeley, CA)	Pediatric AIDS, in combination w/AZT
IMREG-1	Imreg (New Orleans, LA)	AIDS, Kaposi's sarcoma, ARC, PGL
IMREG-2	Imreg (New Orleans, LA)	AIDS, Kaposi's sarcoma, ARC, PGL
Imuthiol Diethyl Dithio Carbamate	Merieux Institute	AIDS, ARC
Alpha-2 Interferon	Schering Plough	Kaposi's sarcoma w/AZT, AIDS
Methionine- Enkephalin	TNI Pharmaceutical (Chicago, IL)	AIDS, ARC
MTP-PE Muramyl-Tripeptide Granulocyte Colony Stimulating Factor	Ciba-Geigy Corp. Amgen	Kaposi's sarcoma AIDS, in combination w/AZT
Remune	Immune Response Corp.	Immunotherapeutic
rCD4 Recombinant Soluble Human CD4	Genentech	AIDS, ARC
rCD4-IgG hybrids		AIDS, ARC
Recombinant Soluble Human CD4	Biogen	AIDS, ARC
Interferon Alfa 2a	Hoffman-La Roche in combination w/AZT	Kaposi's sarcoma, AIDS, ARC
SK&F106528 Soluble T4	Smith Kline	HIV infection
Thymopentin	Immunobiology Research Institute (Annandale, NJ)	HIV infection

Drug Name	Manufacturer	Indication
Tumor Necrosis Factor; TNF	Genentech	ARC, in combination w/gamma Interferon

ANTI-INFECTIVES

Drug Name	Manufacturer	Indication
Clindamycin with Primaquine	Pharmacia Upjohn	PCP
Fluconazole	Pfizer	Cryptococcal meningitis, candidiasis
Pastille Nystatin Pastille	Squibb Corp.	Prevention of oral candidiasis
Ornidyl Eflornithine	Merrell Dow	PCP
Pentamidine Isethionate (IM & IV)	LyphoMed (Rosemont, IL)	PCP treatment
Trimethoprim		Antibacterial
Trimethoprim/sulfa		Antibacterial
Piritrexim	Burroughs Wellcome	PCP treatment
Pentamidine Isethionate for Inhalation	Fisons Corporation	PCP prophylaxis
Spiramycin	Rhone-Poulenc diarrhea	Cryptosporidial
Intraconazole- R51211	Janssen-Pharm.	Histoplasmosis; cryptococcal meningitis
Trimetrexate	Warner-Lambert	PCP
Daunorubicin	NeXstar, Sequus	Kaposi's sarcoma
Recombinant Human Erythropoietin	Ortho Pharm. Corp.	Severe anemia assoc. with AZT therapy
Recombinant Human Growth Hormone	Serono	AIDS-related wasting, cachexia
Megestrol Acetate	Bristol-Myers Squibb	Treatment of anorexia assoc. W/AIDS
Testosterone	Alza, Smith Kline	AIDS-related wasting
Total Enteral Nutrition	Norwich Eaton Pharmaceuticals	Diarrhea and malabsorption related to AIDS

5


DESCRIPTION OF SPECIFIC EMBODIMENTS

In the following experimental procedures, all temperatures are understood to be in Centigrade (C) when not specified. The nuclear magnetic resonance (NMR)

spectral characteristics refer to chemical shifts (δ) expressed in parts per million (ppm) versus tetramethylsilane (TMS) as reference standard. The relative area reported for the various shifts in the proton NMR spectral data corresponds to the number of hydrogen atoms of a particular functional type in the molecule. The nature of the shifts as to multiplicity is reported as broad singlet (bs or br s), broad doublet (bd or br d), broad triplet (bt or br t), broad quartet (bq or br q), singlet (s), multiplet (m), doublet (d), quartet (q), triplet (t), doublet of doublet (dd), doublet of triplet (dt), and doublet of quartet (dq). The solvents employed for taking NMR spectra are acetone- d_6 (deuterated acetone), DMSO- d_6 (perdeuterodimethylsulfoxide), D_2O (deuterated water), $CDCl_3$ (deuteriochloroform) and other conventional deuterated solvents.

The abbreviations used herein are conventional abbreviations widely employed in the art. Some of which are: calcd (calculated); DMSO (dimethylsulfoxide); EtOAc (ethyl acetate); HPLC (high-pressure liquid chromatography); LC/MS (liquid chromatography, mass spectroscopy); LDA (lithium diisopropyl amide); LiHMDS (lithium bis(trimethylsilyl)amide); SiO_2 (silica gel); THF (tetrahydrofuran), TFA (trifluoroacetic acid), Me (methyl), Et (ethyl), Ph (phenyl), tBuOK (potassium tert-butoxide), NaOMe (sodium methoxide), NaOEt (sodium ethoxide), Boc (tert-butoxycarbonyl), and DEAD (diethylazo dicarboxylate).

Intermediate 1




25

2,6-Difluoro-N-hydroxy-N-methyl-benzamidinium. To a stirred solution of 2,6-difluorobenzonitrile (5.565 g, 40 mmol) and N-methylhydroxylamine hydrochloride (10 g, 120 mmol) in 4:1 water/ethanol (100 mL) was added sodium carbonate (8.5 g, 80 mmol) in small portions and the resulting mixture stirred at 100 °C for 2 h. The mixture was then cooled, concentrated and the resulting residue suspended in hot

30

MeOH/CHCl₃ (1:9, 200 mL). The insoluble solids were removed by filtration and concentration of the filtrate gave the desired product as an off-white solid (7.50 g, 100% yield). ¹HNMR (500 MHz, DMSO-d₆) δ: 7.69-7.63 (1H, m), 7.29 (2H, t, J = 8.24 Hz), 6.90 (2H, s), 3.15 (3H, s). LCMS calcd for C₈H₉F₂N₂O (M + H): 187.07; found: 187.12.

Intermediate 2




10

3-(2,6-Difluoro-phenyl)-5-ethoxycarbonylmethyl-2-methyl-2,5-dihydro-[1,2,4]oxadiazole-5-carboxylic acid ethyl ester. A solution of diethyl acetylenedicarboxylate (1.60 mL, 10 mmol) and 2,6-difluoro-N-hydroxy-N-methylbenzamidine (1.862g, 10 mmol) in ethyl alcohol (95% yield) was heated at 80 °C for 1 h. The reaction mixture was then cooled, concentrated and purified on silica gel column eluting with 1:3, 3:7 and 2:3 ethyl acetate/hexanes to give the title compound as a yellow oil (2.691 g, 76% yield). ¹HNMR (500 MHz, CDCl₃) δ: 7.48-7.42 (1H, m), 6.99 (2H, t, J = 8.20 Hz), 4.37-4.24 (2H, m), 4.18 (2H, q, J = 7.02 Hz), 3.40 (1H, d, J 16.48 Hz), 3.11 (1H, d, J = 16.48 Hz), 3.08 (3H, s), 1.32 (3H, t, J 7.02 Hz), 1.26 (3H, t, J = 7.02 Hz). LCMS calcd for C₁₆H₁₉F₂N₂O₅ (M + H): 357.13; found: 357.38.


20

Intermediate 3




2-(2,6-Difluoro-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester. A solution of 3-(2,6-difluoro-phenyl)-5-ethoxycarbonylmethyl-2-methyl-2,5-dihydro-[1,2,4]oxadiazole-5-carboxylic acid ethyl ester (2.68 g, 7.52 mmol) in xylenes (50 mL) was heated at reflux for 1.5 h and cooled to room temperature. The precipitate was filtered and dried to give the title compound as an off-white solid (1.4 g, 60% yield). ¹HNMR (500 MHz, CDCl₃) δ: 10.96 (1H, s), 7.50-7.45 (1H, m), 7.04 (2H, t, J = 7.33 Hz), 4.51 (2H, q, J = 7.02 Hz), 3.41 (3H, s), 1.41 (3H, t, J = 7.02 Hz). HRMS (ESI) calcd for C₁₄H₁₃F₂N₂O₄ (M + H): 311.0844; found: 311.0845.

EXAMPLE 1




15 *N*-(4-fluorobenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. A mixture of ester 2-(2,6-difluoro-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (91 mg, 0.2933 mmol) and 4-fluorobenzylamine (184 mg, 1.5 mmol) in toluene (2 mL) was heated at reflux for 3.5 h. The reaction mixture was then, cooled, concentrated and purified by reverse phase preparative HPLC (C18, methanol/H₂O-0.1%TFA, gradient elution). The fractions containing the product were combined and concentrated to give the title compound as an off-white solid (55 mg, 48% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.30 (1H, s), 7.80 (1H, s), 7.49 (1H, t, J = 6.5 Hz), 7.34-7.22 (2H, m), 7.06-7.00 (4H, m), 4.55 (2H, d, J = 5.5 Hz), 3.40 (3H, s). HRMS (ESI) calcd for C₁₉H₁₅F₃N₃O₃ (M + H): 390.1066; found: 390.1076.

EXAMPLE 2

5 *N*-(3,4-dichlorobenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. A mixture of ester 2-(2,6-difluoro-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (31 mg, 0.1 mmol) and 3,4-dichlorobenzylamine (88 mg, 0.5 mmol) in DMF (1 mL) was heated between 120-130 °C for 3 h. The reaction mixture was then cooled and
10 purified by preparative HPLC (C18, methanol/H₂O-0.1%TFA, gradient elution). The fractions containing the product were combined and concentrated to give the title compound as an off-white solid (41.2 mg, 94% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.15 (1H, s), 7.84 (1H, t, J = 5.5 Hz), 7.53-7.47 (1H, m), 7.41-7.38 (2H, m), 7.16 (1H, dd, J = 8.24, 2.13 Hz), 7.06 (1H, dd, J = 8.54, 7.32 Hz), 4.53 (6.41 Hz), 3.41
15 (3H, s). HRMS (ESI) calcd for C₁₉H₁₄Cl₂F₃N₃O₃ (M + H): 340.0380; found: 340.0383. Anal. calcd for C₁₉H₁₃Cl₂F₃N₃O₃: C 51.83, H 2.97, N 9.54, Cl 16.10, F 8.63; found: C 51.48, H 2.63, N 9.43, Cl 15.71, F 8.52.

EXAMPLE 3


20



N-(3,4-difluorobenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described
25 for example 2 from 2-(2,6-difluoro-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-

pyrimidine-4-carboxylic acid ethyl ester (31 mg, 0.1 mmol) and 3,4-difluorobenzylamine (72 mg, 0.5 mmol). The title product was obtained as an off-white solid (32.7 mg, 80% yield). ^1H NMR (500 MHz, CDCl_3) δ : 12.18 (1H, s), 7.83 (1H, br s), 7.53-7.47 (1H, m), 7.15-7.02 (5H, m), 4.53 (2H, d, $J = 6.41$ Hz), 3.41 (3H, s). HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{14}\text{F}_4\text{N}_3\text{O}_3$ ($M + \text{H}$): 408.0971; found: 408.0969.

EXAMPLE 4




10

N-(4-chlorobenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-(2,6-difluoro-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid ethyl ester (31 mg, 0.1 mmol) and 4-chlorobenzylamine (71 mg, 0.5 mmol). The title product was obtained as an off-white solid (32.3 mg, 80% yield). ^1H NMR (500 MHz, CDCl_3) δ : 12.25 (1H, s), 7.80 (1H, br s), 7.52-7.46 (1H, m), 7.81 (2H, d, $J = 8.55$ Hz), 7.25 (2H, d, $J = 8.24$ Hz), 7.05 (2H, dd, $J = 8.54$, 7.32 Hz), 4.55 (2H, d, $J = 6.10$ Hz), 3.41 (3H, s). HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{15}\text{ClF}_2\text{N}_3\text{O}_3$ ($M + \text{H}$): 406.0770; found: 406.0775.

20


EXAMPLE 5




25

N-(4-methylbenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-(2,6-difluoro-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid ethyl ester (31 mg, 0.1 mmol) and 4-methylbenzylamine (61 mg, 0.5 mmol). The title product was obtained as an off-white solid (32 mg, 83% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.39 (1H, s), 7.55 (1H, br s), 7.51-7.45 (1H, m), 7.20 (2H, d, J = 7.94 Hz), 7.14 (2H, d, J = 7.63 Hz), 7.03 (2H, d, J = 8.55, 7.33 Hz), 4.54 (2H, d, J = 6.10 Hz), 3.40 (3H, s), 2.32 (3H, s). HRMS (ESI) calcd for C₂₀H₁₈F₂N₃O₃ (M + H): 386.1316; found: 386.1313.

EXAMPLE 6




N-(3,4-dimethylbenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-(2,6-difluoro-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid ethyl ester (31 mg, 0.1 mmol) and 3,4-dimethylbenzylamine (68 mg, 0.5 mmol). The title product was obtained as an off-white solid (32.7 mg, 82% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.41 (1H, s), 7.74 (1H, br s), 7.51-7.45 (1H, m), 7.10-7.02 (5H, m), 4.51 (2H, d, J = 6.10 Hz), 3.40 (3H, s), 2.24 (3H, s), 2.23 (3H, s). HRMS (ESI) calcd for C₂₁H₂₀F₂N₃O₃ (M + H): 400.1473; found: 400.01464.

EXAMPLE 7

5 *N*-(3-chloro-4-methylbenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-(2,6-difluoro-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (31 mg, 0.1 mmol) and 3-chloro-4-methylbenzylamine (78 mg, 0.5 mmol). The title product was obtained as
10 an off-white solid (35.3 mg, 84% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.27 (1H, s), 7.78 (1H, br s), 7.53-7.45 (1H, m), 7.31-7.03 (5H, m), 4.52 (2H, d, J = 3.96 Hz), 3.41 (3H, s), 2.33 (3H, s). HRMS (ESI) calcd for C₂₀H₁₇ClF₂N₃O₃ (M + H): 420.0926; found: 420.0929.

15


EXAMPLE 8

20 *N*-(2,4-difluorobenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-(2,6-difluoro-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (31 mg, 0.1 mmol) and 2,4-difluorobenzylamine (72 mg, 0.5 mmol). The title product was obtained as an off-white solid (36.2 mg, 89% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.13 (1H, s), 7.87
25 (1H, br s), 7.06 (2H, dd, J = 8.54, 7.33 Hz), 6.86-6.81 (2H, m), 6.75-6.69 (2H, m),

4.56 (2H, d, $J = 6.41$ Hz), 3.42 (3H, s). HRMS (ESI) calcd for $C_{19}H_{12}F_4N_3O_3$ (M - H): 406.0815; found: 406.0812.

EXAMPLE 9


5



N-(2-methylbenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-(2,6-difluoro-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (31 mg, 0.1 mmol) and 2-methylbenzylamine (61 mg, 0.5 mmol). The title product was obtained as an off-white solid (34.1 mg, 88.6% yield). ^1H NMR (500 MHz, CDCl_3) δ : 12.38 (1H, s), 7.63 (1H, br s), 7.51-7.45 (1H, m), 7.26-7.16 (4H, m), 7.04 (2H, dd, $J = 8.54, 7.32$ Hz), 4.59 (2H, d, $J = 5.79$ Hz), 3.40 (3H, s), 2.33 (3H, s). HRMS (ESI) calcd for $C_{20}H_{16}F_2N_3O_3$ (M - H): 384.1160; found: 384.1171.

15

EXAMPLE 10




20

N-(4-fluoro-2-(trifluoromethyl)benzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-(2,6-difluoro-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (31 mg, 0.1

25

mmol) and 2-trifluoromethyl-4-fluorobenzylamine (97 mg, 0.5 mmol). The title product was obtained as an off-white solid (25.7 mg, 56% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.07 (1H, s), 7.92 (1H, t, J = 5.34), 7.53-7.47 (1H, m), 7.36 (1H, s), 7.24 (2H, d, J = 8.24 Hz), 7.06 (2H, dd, J = 8.54, 7.33 Hz), 4.63 (2H, d, J = 6.41 Hz), 3.42 (3H, s). HRMS (ESI) calcd for C₂₀H₁₂F₆N₃O₃ (M - H): 456.0783; found: 456.0793.

EXAMPLE 11




10

N-(4-(trifluoromethyl)benzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-(2,6-difluoro-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (31 mg, 0.1 mmol) and 4-trifluoromethylbenzylamine (88 mg, 0.5 mmol). The title product was obtained as an off-white solid (38.6 mg, 88% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.18 (1H, s), 7.88 (1H, t, J = 4.58), 7.60 (2H, d, J = 8.24 Hz), 7.53-7.47 (1H, m), 7.43 (2H, d J = 8.24 Hz), 7.05 (2H, dd, J = 8.24, 7.32 Hz), 4.65 (2H, d, J = 6.41 Hz), 3.42 (3H, s). HRMS (ESI) calcd for C₂₀H₁₃F₅N₃O₃ (M - H): 438.0877; found: 438.0878.

20


EXAMPLE 12




25

N-(benzo[d][1,3]dioxol-5-ylmethyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-(2,6-difluoro-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (31 mg, 0.1 mmol) and piperonylamine (76 mg, 0.5 mmol). The title product was obtained as an off-white solid (18.6 mg, 45% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.35 (1H, s), 7.74 (1H, br s), 7.52-7.46 (1H, m), 7.04 (2H, dd, J = 8.24, 7.33 Hz), 6.80 (1H, s), 6.78-6.74 (2H, m), 5.93 (2H, s), 4.48 (2H, d, J = 6.10 Hz), 3.40 (3H, s). HRMS (ESI) calcd for C₂₀H₁₄F₂N₃O₅ (M - H): 414.0902; found: 414.0900.

EXAMPLE 13




2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-*N*-(1-phenylethyl)-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-(2,6-difluoro-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (31 mg, 0.1 mmol) and α-methylbenzylamine (61 mg, 0.5 mmol). The title product was obtained as an off-white solid (24.6 mg, 64% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.39 (1H, s), 7.71 (1H, d, J = 7.94 Hz), 7.54-7.48 (1H, m), 7.36-7.25 (5H, m), 7.06 (2H, dd, J = 14.65, 8.54 Hz), 5.22 (1H, qt, J = 7.02 Hz), 3.40 (3H, s), 1.58 (3H, d, J = 7.02 Hz). HRMS (ESI) calcd for C₂₀H₁₆F₂N₃O₃ (M - H): 384.1160; found: 384.1161.

EXAMPLE 14

5 *N*-(2-(methylthio)benzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-
 1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure
 described for example 2 from 2-(2,6-difluoro-phenyl)-5-hydroxy-1-methyl-6-oxo-
 1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (31 mg, 0.1 mmol) and 2-
 methylthiobenzylamine (77 mg, 0.5 mmol). The title product was obtained as an off-
 10 white solid (34.2 mg, 82% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.37 (1H, s), 7.92
 (1H, br s), 7.55-7.44 (1H, m), 7.33-7.25 (2H, m), 7.17-7.14 (1H, m), 7.04 (2H, dd, J =
 8.24, 7.32 Hz), 4.67 (2H, d, J = 6.10 Hz), 3.40 (3H, s), 2.44 (3H, s). HRMS (ESI)
 calcd for C₂₀H₁₆F₂N₃O₃S (M - H): 416.0880; found: 416.0879.


15

EXAMPLE 15

20 *N*-(3-fluoro-4-(trifluoromethyl)benzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-
 methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the
 procedure described for example 2 from 2-(2,6-difluoro-phenyl)-5-hydroxy-1-
 methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (31 mg, 0.1
 mmol) and 3-fluoro-4-trifluoromethylbenzylamine (97 mg, 0.5 mmol). The title
 product was obtained as an off-white solid (44.7 mg, 98% yield). ¹HNMR (500
 25 MHz, CDCl₃) δ: 12.13 (1H, s), 7.88 (1H, br s), 7.57-7.47 (4H, m), 7.06 (2H, dd, J =


8.54, 7.32 Hz), 4.59 (2H, d, J = 6.41 Hz), 3.41 (3H, s). HRMS (ESI) calcd for $C_{20}H_{12}F_6N_3O_3$ (M - H): 456.0782; found: 456.0788.

EXAMPLE 16



N-(3,5-bis(trifluoromethyl)benzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-(2,6-difluoro-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (31 mg, 0.1 mmol) and 2,5-ditrifluoromethyl-benzylamine (98 mg, 0.5 mmol). The title product was obtained as an off-white solid (43.6 mg, 86% yield). ^1H NMR (500 MHz, CDCl_3) δ : 12.01 (1H, s), 7.98 (1H, t, J = 5.5 Hz), 7.80 (1H, s), 7.77 (2H, s), 7.54-7.47 (1H, m), 7.06 (2H, dd, J = 8.54, 7.32 Hz), 4.70 (2H, d, J = 6.41 Hz), 3.42 (3H, s). HRMS (ESI) calcd for $C_{21}H_{12}F_8N_3O_3$ (M - H): 506.0751; found: 506.0762.


EXAMPLE 17



2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-*N*-(pyridin-2-ylmethyl)-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-(2,6-difluoro-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (31 mg, 0.1 mmol) and 2-

(aminomethyl)pyridine (54 mg, 0.5 mmol). The title product was obtained as a TFA salt, white solid (11 mg, 23% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.00-10.00 (2H, br s), 8.73 (1H, t, J = 5.49 Hz), 8.67 (1H, d, J = 4.88 Hz), 8.19 (1H, t, J = 7.78 Hz), 7.87 (1H, d, J = 7.94 Hz), 7.66 (1H, t, J = 6.56 Hz), 7.53-7.47 (1H, m), 7.05 (2H, dd, J = 8.54, 7.32 Hz), 4.97 (2H, d, J = 6.41 Hz), 3.40 (3H, s). HRMS (ESI) calcd for C₁₈H₁₅F₂N₄O₃ (M + H): 373.1112; found: 373.1119.

EXAMPLE 18




10

N-benzyl-5-hydroxy-1-methyl-6-oxo-2-phenyl-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-(2,6-difluoro-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (62 mg, 0.2 mmol) and benzylamine (64 mg, 0.6 mmol). The title product was obtained as a white solid (45 mg, 61% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.38 (1H, s), 7.82 (1H, br s), 7.53-7.47 (1H, m), 7.37-7.29 (5H, m), 7.25-7.26 (2H, m), 7.07-7.04 (2H, m), 4.60 (2H, d, J = 5.8 Hz), 3.42 (3H, s). HRMS calcd for C₁₉H₁₆F₂N₃O₃ (M + H): 372.1160; found: 372.1156. Anal. Calcd for C₁₉H₁₅F₂N₃O₃: C, 61.45, H, 4.07; N, 11.31; found: C, 61.12, H, 3.77; N, 11.06


20

Intermediate 4




5-Methoxycarbonylmethyl-2-methyl-3-pyridin-2-yl-2,5-dihydro-[1,2,4]oxadiazole-5-carboxylic acid ethyl ester. To a stirred solution of 2-cyanopyridine (2.08 g, 20 mmol) and N-methylhydroxylamine hydrochloride (1.66 g, 20 mmol) in 1:1 water/ethanol (30 mL) was added sodium carbonate (1.04 g, 10 mmol) in small portions. LCMS analysis after 5 min indicated that the reaction was complete. To this was added diethyl acetylenedicarboxylate (3.2 mL, 20 mmol) and the reaction mixture stirred for additional 20 min at room temperature. LCMS analysis of the resulting dark-green reaction showed that the reaction was complete. The reaction mixture was taken up into ethyl acetate (200 mL) and washed successively with water (2 X 25 mL) and brine (25 mL), and the organic layer dried (Na₂SO₄), filtered and concentrated to give brown oil which was passed through a plug of silica gel (1:1 hexanes/ethyl acetate). The filtrate was concentrated to give the title compound as a yellow oil (6.87 g). LCMS calcd for C₁₅H₂₀N₃O₅ (M + H): 322.14 ; found: 322.08.

Intermediate 5




5-Hydroxy-1-methyl-6-oxo-2-pyridin-2-yl-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester. A solution of 5-methoxycarbonylmethyl-2-methyl-3-pyridin-2-yl-2,5-dihydro-[1,2,4]oxadiazole-5-carboxylic acid ethyl ester in xylenes (40 mL) was heated at reflux for 1 h. The reaction mixture was cooled and purified on silica gel column (CH₂Cl₂/5-20% methanol). The fractions containing the product were combined and concentrated to give the title compound as a brown powder (0.705 g, 12.8% yield). ¹HNMR (500 MHz, CDCl₃) δ: 10.75 (1H, br s), 8.66 (1H, d, J = 4.89 Hz), 7.87 (1H, td, J = 7.7, 1.5 Hz), 7.80 (1H, d, J = 7.94 Hz), 7.42-7.39 (1H, m), 4.49 (2H, q, J = 7.02 Hz), 3.63 (3H, s), 1.43 (3H, s). HRMS (ESI) calcd for C₁₃H₁₄N₃O₄ (M + H): 276.098465 ; found: 276.0995.

EXAMPLE 19

5 *N*-(4-chlorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-2-yl)-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 5-hydroxy-1-methyl-6-oxo-2-pyridin-2-yl-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (27.53 mg, 0.1 mmol) and 4-chlorobenzylamine (71 mg, 0.5 mmol). The title product was obtained as a TFA salt
10 (brown solid, 10.3 mg, 21% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.19 (1H, s), 8.70 (1H, d, J = 4.28 Hz), 7.91 (1H, br s), 7.87 (1H, t, J = 6.41 Hz), 7.66 (1H, t, J = 7.63 Hz), 7.44 (1H, dd, J = 7.48, 5.04 Hz), 7.31-7.24 (4H, m), 4.57 (2H, d, J = 6.41 Hz), 3.59 (3H, s). HRMS (ESI) calcd for C₁₈H₁₆ClN₄O₃ (M + H): 371.0911; found: 371.0912.


15

EXAMPLE 20

20 *N*-(3,4-dichlorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-2-yl)-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 5-hydroxy-1-methyl-6-oxo-2-pyridin-2-yl-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (27.53 mg, 0.1 mmol) and 3,4-dichlorobenzylamine (71 mg, 0.5 mmol). The title product was obtained as a TFA
25 salt (off-white solid, 18.6 mg, 36% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.17 (1H,


s), 8.71 (1H, d, $J = 3.97$ Hz), 7.92 (1H, br s), 7.90 (1H, t, $J = 7.63$ Hz), 7.68 (1H, d, $J = 7.63$ Hz), 7.46 (1H, dd, $J = 7.37, 5.18$ Hz), 7.41-7.39 (2H, m), 7.16 (1H, dd, $J = 8.39, 1.98$ Hz), 4.55 (2H, d, $J = 6.41$ Hz), 3.59 (3H, s). HRMS (ESI) calcd for $C_{18}H_{15}Cl_2N_4O_3$ ($M + H$): 405.0521; found: 405.0515.

5

EXAMPLE 21


10 *N*-(3,4-difluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-2-yl)-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 5-hydroxy-1-methyl-6-oxo-2-pyridin-2-yl-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (27.53 mg, 0.1 mmol) and 3,4-difluorobenzylamine (72 mg, 0.5 mmol). The title product was obtained as a TFA
15 salt (brown solid, 11.2 mg, 23% yield). ^1H NMR (500 MHz, CDCl_3) δ : 12.18 (1H, s), 8.72 (1H, d, $J = 4.88$ Hz), 8.02 (1H, br s), 7.91 (1H, td, $J = 1.63, 7.78$ Hz), 7.69 (1H, d, $J = 7.63$ Hz), 7.48 (1H, dd, $J = 7.63, 4.88$ Hz), 7.17-7.03 (3H, m), 4.55 (2H, d, $J = 6.41$ Hz), 3.60 (3H, s). HRMS (ESI) calcd for $C_{18}H_{15}F_2N_4O_3$ ($M + H$): 373.1112; found: 373.1117.

20

EXAMPLE 22


N-(4-methylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-2-yl)-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 5-hydroxy-1-methyl-6-oxo-2-pyridin-2-yl-1,6-dihydropyrimidine-4-carboxylic acid ethyl ester (27.53 mg, 0.1 mmol) and 4-methylbenzylamine (61 mg, 0.5 mmol). The title product was obtained as a TFA salt (brown solid, 14.3 mg, 31% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.37 (1H, s), 8.70 (1H, d, J = 4.58 Hz), 7.91-7.85 (2H, m), 7.66 (1H, d, J = 7.94 Hz), 7.44 (1H, dd, J = 7.02, 4.88 Hz), 7.21 (2H, d, J = 7.93 Hz), 7.15 (1H, d, J = 7.93 Hz), 4.56 (2H, d, J = 6.11 Hz), 3.59 (3H, s), 2.32 (3H, s). HRMS (ESI) calcd for C₁₉H₁₉N₄O₃ (M + H): 351.1457; found: 351.1471.

EXAMPLE 23




15

N-(3,4-dimethylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-2-yl)-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 5-hydroxy-1-methyl-6-oxo-2-pyridin-2-yl-1,6-dihydropyrimidine-4-carboxylic acid ethyl ester (27.53 mg, 0.1 mmol) and 3,4-dimethylbenzylamine (68 mg, 0.5 mmol). The title product was obtained as a TFA salt (brown solid, 14.1 mg, 30% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.36 (1H, s), 8.69 (1H, d, J = 3.97 Hz), 7.88-7.85 (2H, m), 7.66 (1H, d, J = 7.94 Hz), 7.43 (1H, dd, J = 6.71, 4.88 Hz), 7.10-7.03 (3H, m), 4.53 (2H, d, J = 6.10 Hz), 3.59 (3H, s), 2.24 (3H, s), 2.23 (3H, s). HRMS (ESI) calcd for C₂₀H₂₁N₄O₃ (M + H): 365.1614; found: 365.1617.

EXAMPLE 24

5 *N*-(3-chloro-4-methylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-2-yl)-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 5-hydroxy-1-methyl-6-oxo-2-pyridin-2-yl-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (27.53 mg, 0.1 mmol) and 3-chloro-4-methylbenzylamine (78 mg, 0.5 mmol). The title product was obtained as a TFA salt
10 (brown solid, 7.2 mg, 14% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.23 (1H, s), 8.72 (1H, d, J = 4.27 Hz), 7.92 (1H, br s), 7.91 (1H, t, J = 7.18 Hz), 7.69 (1H, d, J = 7.63 Hz), 7.47 (1H, dd, J = 7.47, 5.04 Hz), 7.29 (1H, s), 7.19 (1H, d, J = 7.63 Hz), 7.11 (1H, d, J = 7.93 Hz), 4.54 (2H, d, J = 6.11 Hz), 3.60 (3H, s), 2.34 (3H, s). HRMS (ESI) calcd for C₁₉H₁₈ClN₄O₃ (M + H): 385.1068; found: 385.1076.


15

EXAMPLE 25

20 *N*-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-2-yl)-1,6-dihydropyrimidine-4-carboxamide. A mixture of 5-hydroxy-1-methyl-6-oxo-2-pyridin-2-yl-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (27.53 mg, 0.1 mmol) and 4-fluorobenzylamine (63 mg, 0.5 mmol) in toluene (2 mL) was heated at reflux for 6 h then cooled, concentrated and purified by preparative HPLC (C18,
25 methanol/H₂O-0.1% TFA, gradient elution). The fractions containing the product

were combined and concentrated to give the title compound as a TFA salt (brown paste, 9.6 mg, 21% yield). ^1H NMR (500 MHz, CDCl_3) δ : 12.52-12.30 (1H, br s), 8.71 (1H, d, $J = 4.27$ Hz), 7.90-7.84 (2H, m), 7.66 (1H, d, $J = 7.63$ Hz), 7.45 (1H, td, $J = 7.63, 4.88$ Hz), 7.30-7.27 (2H, m), 7.05-7.00 (2H, m), 4.57 (2H, d, $J = 6.10$ Hz), 3.58 (3H, s). HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{16}\text{FN}_4\text{O}_3$ ($\text{M} + \text{H}$): 355.1207; found: 355.1215.

Intermediate 6




10

N-Hydroxy-2-methoxy-*N*-methyl-benzamidine. To a stirred solution of 2-methoxybenzonitrile (2.66 g, 20 mmol) and *N*-methylhydroxylamine hydrochloride (3.341 g, 40 mmol) in 2:1 water/ethanol (30 mL) was added sodium carbonate (2.332 g, 22 mmol) in small portions and the resulting pink solution stirred at 80 °C for 28 h. The reaction mixture was then concentrated and the residue stirred with CH_2Cl_2 , filtered and concentrated to give crude product as a purple solid (3.3 g), which was used in the next step without further purification.

20

Intermediate 7




5-Ethoxycarbonylmethyl-3-(2-methoxy-phenyl)-2-methyl-2,5-dihydro-[1,2,4]oxadiazole-5-carboxylic acid ethyl ester. To a stirred solution of *N*-hydroxy-


25

2-methoxy-N-methyl-benzamidine (3.3 g) in ethanol (100%) was added diethyl acetylenedicarboxylate (3.2 mL, 20 mmol) and the resulting mixture stirred for 2 h at room temperature. The reaction mixture was then concentrated and purified on silica gel column using (3:7 to 2:3 ethyl acetate/hexanes) to afford the title product as a yellow oil (4.93 g, 70% yield). ¹HNMR (500 MHz, CDCl₃) δ: 7.56 (1H, dd, 7.6, 1.5 Hz), 7.44 (1H, td, J = 7.6, 1.6 Hz), 6.99 (1H, t, 7.5 Hz), 6.95 (1H, d, J = 8.2 Hz), 4.36-4.10 (4H, m), 3.85 (3H, s), 3.43 (1H, d, J = 16.48 Hz), 3.05 (3H, s), 3.04 (1H, d, J = 16.48 Hz), 1.32 (3H, t, J = 7.02 Hz), 1.25 (3H, t, J = 7.02 Hz). HRMS (ESI) calcd for C₁₇H₂₃N₂O₆ (M + H): 351.1556; found: 351.1553.

Intermediate 8




5-Hydroxy-2-(2-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester. A solution of 5-ethoxycarbonylmethyl-3-(2-methoxy-phenyl)-2-methyl-2,5-dihydro-[1,2,4]oxadiazole-5-carboxylic acid ethyl ester (4.916 g, 14.03 mmol) in xylenes (30 mL) was heated at reflux for 3 h, cooled to room temperature and diluted with hexanes (30 mL). The resulting mixture was left in the refrigerator (5 °C) for 48 h. The liquid was decanted and dried to give the title product as a red solid (1.813 g, 43% yield). ¹HNMR (500 MHz, CDCl₃) δ: 10.76 (1H, s), 7.45 (1H, td, J = 7.33, 1.53 Hz), 7.34 (1H, d, J = 7.32 Hz), 7.06 (1H, t, J = 7.32 Hz), 6.94 (1H, d, J = 8.55 Hz), 4.55-4.41 (2H, m), 3.79 (3H, s), 3.34 (3H, s), 1.40 (3H, t, J = 7.02 Hz). HRMS (ESI) calcd for C₁₅H₁₅N₂O₅ (M + H): 303.0981; found: 303.0980.

EXAMPLE 26

5 *N*-(3,4-dichlorobenzyl)-5-hydroxy-2-(2-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 5-Hydroxy-2-(2-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (45.6 mg, 0.15 mmol) and 3,4-dichlorobenzylamine (132 mg, 0.75 mmol). The title product was obtained as a pink
10 solid (55.5 mg, 85% yield). ¹HNMR (500 MHz, CDCl₃) δ: 11.98 (1H, s), 7.95 (1H, t, J = 5.19 Hz), 7.49 (1H, td, J = 7.33, 1.83 Hz), 7.40-7.38 (2H, m), 7.29 (1H, dd, J = 7.63, 1.83 Hz), 7.15 (1H, dd, J = 8.24, 1.83 Hz), 7.07 (1H, t, J = 8.24 Hz), 4.51 (2H, d, J = 6.41 Hz), 3.82 (3H, s), 3.35 (3H, s). HRMS (ESI) calcd for C₂₀H₁₈Cl₂N₃O₄ (M + H): 434.0675; found: 434.0674.


15

EXAMPLE 27

20 *N*-(4-fluorobenzyl)-5-hydroxy-2-(2-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 5-hydroxy-2-(2-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (45.6 mg, 0.15 mmol) and 4-fluorobenzylamine (95 mg, 0.75 mmol). The title product was obtained as a pink
25 solid (37 mg, 64% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.13 (1H, s), 7.90 (1H, t, J


= 5.50 Hz), 7.48 (1H, td, $J = 7.02, 1.83$ Hz), 7.29-7.26 (3H, m), 7.06 (1H, t, $J = 7.33$ Hz), 7.02-6.97 (3H, m), 4.53 (2H, d, $J = 6.41$ Hz), 3.81 (3H, s), 3.34 (3H, s). HRMS (ESI) calcd for $C_{20}H_{19}FN_3O_4$ ($M + H$): 384.1360; found: 384.1370.

5

EXAMPLE 28

N-(3,4-dimethylbenzyl)-5-hydroxy-2-(2-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 5-hydroxy-2-(2-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid ethyl ester (45.6 mg, 0.15 mmol) and 3,4-dimethylbenzylamine (102 mg, 0.75 mmol). The title product was obtained as a brown solid (53.5 mg, 91% yield). ^1H NMR (500 MHz, CDCl_3) δ : 12.50-11.95 (1H, br s), 7.85 (1H, t, $J = 4.58$ Hz), 7.47 (1H, td, $J = 8.24, 1.83$ Hz), 7.27 (1H, dd, $J = 17.63, .83$ Hz), 7.09-7.02 (4H, m), 6.97 (1H, d, $J = 8.24$ Hz), 4.49 (2H, d, $J = 5.79$ Hz), 3.81 (3H, s), 3.34 (3H, s), 2.23 (3H, s), 2.22 (3H, s). HRMS (ESI) calcd for $C_{22}H_{24}N_3O_4$ ($M + H$): 394.1767; found: 394.1781.

20


EXAMPLE 29

N-(3-chloro-4-methylbenzyl)-5-hydroxy-2-(2-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure

25

described for example 2 from 5-hydroxy-2-(2-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (45.6 mg, 0.15 mmol) and 3-chloro-4-methylbenzylamine (107 mg, 0.75 mmol). The title product was obtained as a brown solid (57.5 mg, 93% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.04 (1H, br s), 7.90 (1H, t, J = 5.49 Hz), 7.48 (1H, td, J = 8.24, 1.83 Hz), 7.30-7.25 (2H, m), 7.17 (1H, d, J = 7.94 Hz), 7.10-7.05 (2H, m), 6.98 (1H, d, J = 8.55 Hz), 4.50 (2H, d, J 6.41 Hz), 3.82 (3H, s), 3.34 (3H, s), 2.34 (3H, s). HRMS (ESI) calcd for C₂₁H₂₁ClN₃O₄ (M + H): 414.1221; found: 414.1234.

10


Intermediate 9

5-Ethoxycarbonylmethyl-3-(4-fluoro-2-methanesulfonyl-phenyl)-2-methyl-2,5-dihydro-[1,2,4]oxadiazole-5-carboxylic acid ethyl ester. To a stirred suspension of 4-fluoro-2-(methylsulfonyl)benzonitrile (prepared according to the procedure described in Anthony, N. J. et al PCT Appl. WO 02/30931, 2002) (2.2 g, 11 mmol) and N-methylhydroxylamine hydrochloride (1.66 g, 20 mmol) in 1:1 water/ethanol (40 mL) was added sodium carbonate (1.06 g, 10 mmol) in small portions and the resulting mixture stirred at 80 °C for 3 h. The reaction mixture was concentrated and the residue was re-dissolved into 1:1 water :ethanol (50 mL). To this solution was added diethyl acetylene-dicarboxylate (1.92 mL, 12 mmol) and the resulting mixture stirred for 30 min at room temperature. The reaction mixture was then taken-up into ethyl acetate (150 mL), washed successively with water and brine (50 mL each), dried (MgSO₄), filtered and concentrated to give yellow oil. The crude product was purified on silica gel column (3:7 to 2:3 ethyl acetate/hexanes) to afford the title

product as a white solid (2.9122 g, 64% yield). ^1H NMR (500 MHz, CDCl_3) δ : 7.89 (1H, dd, $J = 8.09, 2.59$ Hz), 7.62 (1H, dd, $J = 8.39, 5.04$ Hz), 7.40 (1H, td, $J = 8.24, 2.44$ Hz), 4.35-4.26 (2H, m), 4.19-4.13 (2H, m), 3.40 (3H, s), 3.38 (1H, d, $J = 16.17$ Hz), 3.15 (1H, d, $J = 16.17$ Hz), 3.02 (3H, s), 1.36-1.30 (3H, m), 1.27-1.23 (3H, m).

5 HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{22}\text{FN}_2\text{O}_7\text{S}$ ($M + \text{H}$): 417.1132 ; found: 417.1116.

Intermediate 10




10


2-(4-Fluoro-2-methanesulfonyl-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester. A solution of 5-ethoxycarbonylmethyl-3-(4-fluoro-2-methanesulfonyl-phenyl)-2-methyl-2,5-dihydro-[1,2,4]oxadiazole-5-carboxylic acid ethyl ester (2.91 g, 6.988 mmol) in xylenes (30 mL) was placed in pre-heated oil bath and refluxed for 6 h,. Heating was stopped and the reaction mixture was allowed to cool slowly to room temperature. The precipitated product was separated by decanting the solvent, rinsed with ether and dried to give the title compound as a yellow solid (1.2192 g, 47% yield). ^1H NMR (500 MHz, CDCl_3) δ : 10.57 (1H, s), 7.90 (1H, dd, $J = 7.93, 2.44$ Hz), 7.49-7.42 (2H, m), 4.54-4.47 (1H, m), 4.41-4.34 (1H, m), 3.31 (3H, s), 3.30 (3H, s), 1.35 (3H, t, $J = 7.02$ Hz). HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{16}\text{FN}_2\text{O}_6\text{S}$ ($M + \text{H}$): 371.0713; found: 371.0724.

20

25

EXAMPLE 30

5 *N*-(4-fluorobenzyl)-2-(4-fluoro-2-(methylsulfonyl)phenyl)-5-hydroxy-1-
methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the
procedure described for example 2 from 2-(4-fluoro-2-methanesulfonyl-phenyl)-5-
hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (55.56
mg, 0.15 mmol) and 4-fluorobenzylamine (125 mg, 1.0 mmol). The title product was
10 obtained as a white solid (61 mg, 68% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.16
(1H, s), 7.87 (1H, dd, J = 7.78, 2.59 Hz), 7.53 (1H, t, J 5.50 Hz), 7.48 (1H, td, J =
7.86, 2.65 Hz), 7.41 (1H, dd, J = 8.54, 4.88 Hz), 7.23 (2H, dd, J = 8.55, 5.50 Hz),
7.00 (2H, t, J = 8.54 Hz), 4.55 (1H, dd, J = 14.95, 6.40 Hz), 4.51 (1H, dd, J = 14.95,
6.10 Hz), 3.26 (3H, s), 3.01 (3H, s). HRMS (ESI) calcd for C₂₀H₁₈F₂N₃O₅S (M + H):
15 450.0935; found: 450.0941.


EXAMPLE 31

20

N-(3,4-dichlorobenzyl)-2-(4-fluoro-2-(methylsulfonyl)phenyl)-5-hydroxy-1-
methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the
procedure described for example 2 from 2-(4-fluoro-2-methanesulfonyl-phenyl)-5-


hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (74.07 mg, 0.20 mmol) and 3,4-dichlorobenzylamine (132 mg, 0.75 mmol). The title product was obtained as a pink solid (69 mg, 92% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.00 (1H, s), 7.87 (1H, dd, J = 7.63, 2.45 Hz), 7.60 (1H, t, J = 7.60 Hz), 7.50-7.42 (2H, m), 7.39 (1H, d, J = 7.93 Hz), 7.32 (1H, s), 7.11 (1H, d, J = 7.32 Hz), 4.55 (1H, dd, J = 15.26, 6.41 Hz), 4.49 (1H, dd, J = 15.26, 6.10 Hz), 3.26 (3H, s), 3.06 (3H, s). HRMS (ESI) calcd for C₂₀H₁₇Cl₂FN₃O₅S (M + H): 500.0250; found: 500.0259.

10


EXAMPLE 32

N-(3,4-dimethylbenzyl)-2-(4-fluoro-2-(methylsulfonyl)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-(4-fluoro-2-methanesulfonyl-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (55.56 mg, 0.15 mmol) and 3,4-dimethylbenzylamine (102 mg, 0.75 mmol). The title product was obtained as a pink solid (59.8 mg, 87% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.25 (1H, s), 7.86 (1H, dd, J = 7.63, 2.44 Hz), 7.49-7.44 (2H, m), 7.41 (1H, dd, J = 8.54, 4.88 Hz), 7.07 (1H, d, J = 7.63 Hz), 7.01 (1H, s), 6.97 (1H, d, J = 7.63 Hz), 4.53 (1H, dd, J = 14.65, 6.41 Hz), 4.43 (1H, dd, J = 14.96, 5.49 Hz), 3.26 (3H, s), 3.01 (3H, s), 2.22 (6H, s). HRMS (ESI) calcd for C₂₂H₂₃FN₃O₅S (M + H): 460.1343; found: 460.1337.

25

EXAMPLE 33

- 5 2-(4-Fluoro-2-methanesulfonyl-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid 3-chloro-4-methyl-benzylamide. Prepared according to the procedure described for example 2 from 2-(4-fluoro-2-methanesulfonyl-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (55.56 mg, 0.15 mmol) and 3-chloro-4-methylbenzylamine (107 mg, 0.75 mmol). The title product was obtained as a pink solid (58.6 mg, 81% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.12 (1H, s), 7.87 (1H, dd, J = 7.63, 2.45 Hz), 7.53 (1H, t, J = 5.50 Hz), 7.48 (1H, td, J = 7.62, 2.74 Hz), 7.42 (1H, dd, J = 8.24, 4.89 Hz), 7.20 (1H, s), 7.17 (1H, d, J = 7.63 Hz), 7.05 (1H, d, J = 7.63 Hz), 4.57 (1H, dd, J = 14.95, 6.72 Hz), 4.43 (1H, dd, J = 14.95, 5.49 Hz), 3.26 (3H, s), 3.05 (3H, s), 2.33 (3H, s). HRMS (ESI) calcd for C₂₁H₂₀ClFN₃O₅S (M + H): 480.0796; found: 480.0793.


Intermediate 11

20


- 25 2-Fluoro-6-methylamino-benzonitrile. To a stirred solution of 2,6-difluorobenzonitrile (3.5 g, 25.2 mmol) in ethanol (40 mL) was added 2 mL of methylamine (40 wt%, in H₂O) and heated at 80 °C for 2 h. The mixture was then diluted with water and the resulting slurry extracted with dichloromethane (3 X 50 mL). The combined organic extracts were dried (Na₂SO₄), filtered and concentrated

to give the title product as a white solid (3.77 g, 99.6% yield). ^1H NMR (500 MHz, CDCl_3) δ : 7.35-7.31 (1H, m), 6.41-6.38 (2H, m), 4.74 (1H, br s), 2.93 (3H, d, $J = 5.19$ Hz). LCMS calcd for $\text{C}_8\text{H}_8\text{FN}_2$ ($M + \text{H}$): 151.07; found: 151.07.

5

Intermediate 12

N-(2-Cyano-3-fluoro-phenyl)-*N*-methyl-methanesulfonamide. To a stirred
10 solution of 2-fluoro-6-methylamino-benzonitrile (1.5 g, 10 mmol) in THF (50 mL) at
-78 °C was added LiHMDS (1M in THF, 16 mL, 16 mmol) dropwise over 5 min.
The resulting pale yellow solution was stirred for an additional 30 min, then
methanesulfonyl chloride (1.16 mL, 15 mmol) was added. After 30 min, the reaction
mixture was quenched with saturated NH_4Cl (1 mL), diluted with ethyl acetate (100
15 mL), dried (MgSO_4), filtered and concentrated to give viscous yellow oil. The crude
product was purified on silica gel column (2:3 EtOAc/hexanes) to give the title
compound as a white solid (1.5936 g, 70% yield). ^1H NMR (500 MHz, CDCl_3) δ :
7.65-7.61 (1H, m), 7.86 (1H, d, $J = 8.24$ Hz), 7.22 (1H, t, $J = 8.24$ Hz), 3.38 (3H, s),
3.13 (3H, s). HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{22}\text{FN}_2\text{O}_7\text{S}$ ($M + \text{H}$): 417.1132; found:
20 417.1116.


Intermediate 13

25

5-*Ethoxycarbonylmethyl-3-[2-fluoro-6-(methanesulfonyl-methyl-amino)-phenyl]-2-methyl-2,5-dihydro-[1, 2,4]oxadiazole-5-carboxylic acid ethyl ester*. To a stirred suspension of N-(2-cyano-3-fluoro-phenyl)-N-methyl-methanesulfonamide (0.685 g, 3.0 mmol) and N-methylhydroxylamine hydrochloride (1.0 g, 12 mmol) in 1:1 water/ethanol (20 mL) was added sodium carbonate (0.936 g, 6 mmol) in small portions and the resulting mixture stirred at 80 °C for 4 h. The reaction mixture was concentrated and the residue re-dissolved into 1:1 water :ethanol (20 mL). To this solution was added diethyl acetylenedicarboxylate (0.64 mL, 4 mmol) and the mixture stirred for 1 h at room temperature. The reaction mixture was then taken up in ethyl acetate (100 mL), washed successively with water and brine (50 mL each), dried (MgSO₄), filtered and concentrated to give a yellow oil. The crude product was purified on silica gel column (2:3 to 3:2 ethyl acetate/hexanes) to afford the title compound as a viscous yellow oil (0.7453 g, 56% yield). ¹HNMR (500 MHz, CDCl₃) δ: 7.52-7.48 (1H, m), 7.31 (1H, d, J = 8.24 Hz), 7.18 (1H, t, J = 8.55 Hz), 4.35-4.25 (2H, m), 4.18 (2H, q, J = 7.02 Hz), 3.40 (1H, d, J = 16.48 Hz), 3.21 (3H, s), 3.09 (1H, d, J = 16.48 Hz), 3.09 (3H, s), 3.07 (3H, s), 1.33 (3H, t, J = 7.02 Hz), 1.26 (3H, t, J = 7.02 Hz). HRMS (ESI) calcd for C₁₈H₂₅FN₃O₇S (M + H): 446.1397; found: 446.1383.

20


Intermediate 14



25 2-[2-Fluoro-6-(methanesulfonyl-methyl-amino)-phenyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester. A solution of 5-ethoxycarbonylmethyl-3-[2-fluoro-6-(methanesulfonyl-methyl-amino)-phenyl]-2-methyl-2,5-dihydro-[1, 2,4]oxadiazole-5-carboxylic acid ethyl ester (740 mg, 1.6612 mmol) in xylenes (10 mL) was placed in a pre-heated oil bath and heated to reflux for 2 h. Heating was stopped and the reaction mixture was allowed to cool slowly to

room temperature. The precipitated product was separated by decanting the solvent, then rinsed with ether and dried to give the title compound as a yellow solid (374.8 mg, 56% yield). ¹HNMR (500 MHz, CDCl₃) δ: 10.65 (1H, s), 7.57-7.52 (1H, m), 7.28 (1H, d, J = 7.94 Hz), 7.22 (1H, t, J = 8.85 Hz), 4.55-4.49 (1H, m), 4.40-4.33 (1H, m), 3.46 (3H, s), 3.30 (3H, s), 2.90 (3H, s), 1.37 (3H, t, J = 7.02 Hz). HRMS (ESI) calcd for C₁₆H₁₉FN₃O₆S (M + H): 400.0979; found: 400.0979.

EXAMPLE 34




10

N-(4-fluorobenzyl)-2-(2-fluoro-6-(*N*-methylmethanesulfonylphenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-[2-fluoro-6-(methanesulfonyl-methyl-amino)-phenyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid ethyl ester (60 mg, 0.15 mmol) and 4-fluorobenzylamine (95 mg, 0.75 mmol). The title product was obtained as a pink solid (64.2 mg, 89% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.14 (1H, s), 7.76 (1H, t, J = 5.50 Hz), 7.57-7.53 (1H, m), 7.28-7.21 (4H, m), 7.03-6.98 (2H, m), 4.59 (1H, dd, J = 14.65, 6.71 Hz), 4.47 (1H, dd, J = 14.96, 5.80 Hz), 3.42 (3H, s), 3.08 (3H, s), 2.86 (3H, s). HRMS (ESI) calcd for C₂₁H₂₁F₂N₄O₅S (M + H): 479.1201; found: 479.1196.


20

EXAMPLE 35



25


N-(3,4-dichlorobenzyl)-2-(2-fluoro-6-(*N*-methylethanesulfonyl-sulfonamido)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-[2-fluoro-6-(methanesulfonyl-methyl-amino)-phenyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (60 mg, 0.15 mmol) and 3,4-dichlorobenzylamine (132 mg, 0.75 mmol). The title product was obtained as a pink solid (68.2 mg, 86% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.00 (1H, s), 7.85 (1H, t, J = 5.50 Hz), 7.59-7.54 (1H, m), 7.39 (1H, d, J = 8.54 Hz), 7.38 (1H, s), 7.26-7.22 (2H, m), 7.15 (1H, dd, J = 8.24, 2.13 Hz), 4.59 (1H, dd, J = 15.26, 6.72 Hz), 4.45 (1H, dd, J = 15.26, 5.80 Hz), 3.43 (3H, s), 3.12 (3H, s), 2.91 (3H, s). HRMS (ESI) calcd for C₂₁H₂₀Cl₂FN₄O₅S (M + H): 529.0516; found: 529.0505.

EXAMPLE 36


15

N-(3-chloro-4-methylbenzyl)-2-(2-fluoro-6-(*N*-methylethanesulfonyl-sulfonamido)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-[2-fluoro-6-(methanesulfonyl-methyl-amino)-phenyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (60 mg, 0.15 mmol) and 3-chloro-4-methylbenzylamine (107 mg, 0.75 mmol). The title product was obtained as a pink solid (59.8 mg, 78% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.11 (1H, s), 7.76 (1H, t, J = 5.50 Hz), 7.58-7.53 (1H, m), 7.26-7.21 (3H, m), 7.17 (1H, d, J = 7.63 Hz), 7.08 (1H, dd, J = 7.93, 1.52 Hz), 4.58 (1H, dd, J = 14.95, 6.72 Hz), 4.43 (1H, dd, J = 14.95, 5.50 Hz), 3.43 (3H, s), 3.12 (3H, s), 2.87 (3H, s), 2.33 (3H, s). HRMS (ESI) calcd for C₂₂H₂₃ClFN₄O₅S (M + H): 509.1062; found: 509.1055.

25


Intermediate 15

- 5 *3-(2,6-Dimethoxy-phenyl)-5-ethoxycarbonylmethyl-2-methyl-2,5-dihydro-[1,2,4]oxadiazole-5-carboxylic acid ethyl ester.* To a stirred suspension of 2,6-dimethoxy-benzonitrile (0.82 g, 5 mmol) and N-methylhydroxylamine hydrochloride (1.66 g, 20 mmol) in 1:1 water/ethanol (20 mL) was added sodium carbonate (1.05 g, 10 mmol) in small portions and the resulting mixture stirred at 80 °C for 24 h. The
- 10 reaction mixture was concentrated and the residue was re-dissolved into 1:1 water:ethanol (25 mL). To this solution was added diethyl acetylenedicarboxylate (0.96 mL, 6 mmol) and the resulting mixture stirred for 30 min at room temperature. The reaction mixture was then taken up in ethyl acetate (100 mL), washed successively with water and brine (50 mL each), dried (Na₂SO₄), filtered and concentrated to give
- 15 a yellow oil. The crude product was purified on silica gel column (3:7 to 1:1 ethyl acetate/hexanes) to afford the title compound as a viscous yellow (1.5795 g, 83% yield). ¹HNMR (500 MHz, CDCl₃) δ: 7.32 (1H, t, J = 8.24 Hz), 6.55 (2H, d, J = 8.24 Hz), 4.38-4.24 (2H, m), 4.20-4.14 (2H, m), 3.80 (6H, s), 3.48 (1H, d, J = 16.48 Hz), 3.03 (1H, d, J = 16.48 Hz), 3.02 (3H, s), 1.33 (3H, t, J = 7.02 Hz), 1.26 (3H, t, J =
- 20 7.02 Hz). HRMS (ESI) calcd for C₁₈H₂₅N₂O₇S (M + H): 381.1662; found: 381.1656.

Intermediate 16

2-(2,6-Dimethoxy-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester. A solution of 3-(2,6-dimethoxy-phenyl)-5-ethoxycarbonylmethyl-2-methyl-2,5-dihydro-[1,2,4]oxadiazole-5-carboxylic acid ethyl ester (1.577 g, 4.1457 mmol) in xylenes (15 mL) was placed in a pre-heated oil bath and refluxed for 2 h. Heating was stopped and the reaction mixture was allowed to cool slowly to room temperature. The precipitated product was separated by decanting the solvent, rinsed with ether and dried to give the title compound as a brown solid (1.386 g, 62% yield). ¹HNMR (500 MHz, CDCl₃) δ: 10.83 (1H, s), 7.35 (1H, t, J = 8.54 Hz), 6.59 (2H, d, J = 8.54 Hz), 4.50 (2H, q, J = 7.02 Hz), 3.75 (6H, s), 3.28 (3H, s), 1.39 (3H, t, J = 7.02 Hz). HRMS (ESI) calcd for C₁₆H₁₉N₂O₆ (M + H): 335.1243; found: 335.1240.


EXAMPLE 37



15


N-(4-fluorobenzyl)-2-(2,6-dimethoxyphenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-(2,6-dimethoxy-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (50 mg, 0.15 mmol) and 4-fluorobenzylamine (125 mg, 1.0 mmol). The title product was obtained as a pink solid (48.7 mg, 79% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.10 (1H, s), 7.92 (1H, t, J = 5.50 Hz), 7.39 (1H, t, J = 8.54 Hz), 7.30 (1H, d, J = 5.19 Hz), 7.28 (1H, d, J = 5.19 Hz), 7.00 (2H, t, J = 8.54 Hz), 6.62 (2H, d, J = 8.24 Hz), 4.52 (2H, d, J = 6.40 Hz), +3.75 (6H, s), 3.28 (3H, s). HRMS (ESI) calcd for C₂₁H₂₁FN₃O₅ (M + H): 414.1465; found: 414.1454.

25

EXAMPLE 38

5 *N*-(3,4-dichlorobenzyl)-2-(2,6-dimethoxyphenyl)-5-hydroxy-1-methyl-6-oxo-
1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure
described for example 2 from 2-(2,6-dimethoxy-phenyl)-5-hydroxy-1-methyl-6-oxo-
1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (74.07 mg, 0.20 mmol) and 3,4-
dichlorobenzylamine (132 mg, 0.75 mmol). The title product was obtained as a pink
10 solid (57.8 mg, 83% yield). ¹HNMR (500 MHz, CDCl₃) δ: 11.95 (1H, s), 7.97 (1H, t, J = 5.50 Hz), 7.41-7.38 (3H, m), 7.16 (1H, dd, J = 8.24, 2.14 Hz), 6.63 (2H, d, J = 8.24 Hz), 6.50 (2H, d, J = 6.40 Hz), 3.76 (6H, s), 3.29 (3H, s). HRMS (ESI) calcd for C₂₁H₂₀Cl₂N₃O₅ (M + H): 464.0780; found: 464.0775.

15


EXAMPLE 39

20 *N*-(3,4-dimethylbenzyl)-2-(2,6-dimethoxyphenyl)-5-hydroxy-1-methyl-6-oxo-
1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure
described for example 2 from 2-(2,6-dimethoxy-phenyl)-5-hydroxy-1-methyl-6-oxo-
1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (50 mg, 0.15 mmol) and 3,4-
dimethylbenzylamine (102 mg, 0.75 mmol). The title product was obtained as a
brown solid (52 mg, 82% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.28 (1H, s), 7.88
25 (1H, t, J = 5.50 Hz), 7.38 (1H, t, J = 8.24 Hz), 7.10-7.03 (3H, m), 6.61 (2H, d, J =

8.54 Hz), 4.48 (2H, d, J = 6.11 Hz), 3.75 (6H, s), 3.28 (3H, s), 2.23 (3H, s), 2.22 (3H, s). HRMS (ESI) calcd for $C_{23}H_{26}N_3O_5$ (M + H): 424.1873; found: 424.1863.

EXAMPLE 40


5



N-(3-chloro-4-methylbenzyl)-2-(2,6-dimethoxyphenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-(2,6-dimethoxy-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (50 mg, 0.15 mmol) and 3-chloro-4-methylbenzylamine (107 mg, 0.75 mmol). The title product was obtained as a pink solid (51.1 mg, 77% yield). ^1H NMR (500 MHz, CDCl_3) δ : 12.09 (1H, s), 7.92 (1H, t, J = 5.50 Hz), 7.39 (1H, t, J = 8.24 Hz), 7.28 (1H, d, J = 1.22 Hz), 7.17 (1H, d, J = 7.63 Hz), 7.10 (1H, dd, J = 7.63, 1.53 Hz), 6.62 (2H, d, J = 8.24 Hz), 4.49 (2H, d, J = 6.40 Hz), 3.76 (6H, s), 3.28 (3H, s), 2.33 (3H, s). HRMS (ESI) calcd for $C_{22}H_{23}\text{ClN}_3\text{O}_5$ (M + H): 444.1326; found: 444.1327.

20


Intermediate 17



2-(1,1-Dioxo-1,2,3,4-tetrahydro-1,2-thiazin-2-yl)-benzonitrile. To a suspension of sodium hydride (0.54 g, 95%, 20 mmol) in DMF (25 mL) was added [1,2]thiazinane 1,1-dioxide (2.70g, 20 mmol). After stirring the mixture at room temperature for 15 min, 2-fluorobenzonitrile (2.7 mL, 25 mmol) was added and the resulting mixture was stirred at 80 °C for 18 h, cooled, diluted with water and the resulting solid


filtered. The mother liquor was concentrated and the residue was recrystallized from 1:1 ethyl acetate/hexanes to yield the title product as an orange solid (3.47g, 74% yield). ¹HNMR (500 MHz, CDCl₃) δ: 7.69 (1H, dd, J = 7.63, 1.23 Hz), 7.62-7.55 (2H, m) 7.40 (1H, t, J = 7.63 Hz), 3.72 (2H, t, J = 5.19 Hz), 3.31 (2H, t, J = 6.10 Hz), 2.39-2.34 (2H, m), 2.04-1.99 (2H, m). LCMS calcd for C₁₁H₁₃N₂O₂S (M + H): 237.29; found: 237.26.

Intermediate 18




2-(1,1-Dioxo-1λ⁶-[1,2]thiazinan-2-yl)-N-hydroxy-N-methyl-benzamidinium. To a stirred solution of 2-(1,1-dioxo-1λ⁶-[1,2]thiazinan-2-yl)-benzonitrile and N-methylhydroxylamine hydrochloride (1.67 g, 20 mmol) in 1:1 water/ethanol (70 mL) was added sodium carbonate (1.06 g, 10 mmol) and the resulting mixture stirred at 90 °C for 18h. After cooling and concentration, the resulting residue was suspended in MeOH/CHCl₃ (100 mL, 1:9). The insoluble solids were removed by filtration and concentration of the filtrate gave the crude product as an amber oil (3.5 g) that was carried on without further purification. LCMS calcd for C₁₂H₁₇N₃O₃S (M + H): 284.35; found: 284.27.

Intermediate 19



3-[2-(1,1-Dioxo-1 λ^6 -[1,2]thiazinan-2-yl)-phenyl]-5-ethoxycarbonylmethyl-2-methyl-2,5-dihydro-[1,2,4]oxadiazole-5-carboxylic acid ethyl ester. To a stirred solution of 2-(1,1-dioxo-1 λ^6 -[1,2]thiazinan-2-yl)-N-hydroxy-N-methyl-benzamidinium (3.5 g) in ethanol (100 mL, 200 proof) was added diethyl acetylene-dicarboxylate (3.2 mL, 20 mmol) and the resulting mixture stirred at room temperature for 30 min. The mixture was concentrated and purified on a silica gel column (10%-30% ethyl acetate/hexanes) to afford the title compound as a yellow oil (3.62 g, 40% yield). ¹HNMR (300 MHz, CDCl₃) δ : 7.57 (2H, td, J = 7.14, 1.28 Hz), 7.50 (1H, td, J = 7.68, 1.83 Hz), 7.39 (1H, td, J = 7.50, 1.46 Hz), 4.34-4.22 (2H, m), 4.18 (2H, q, J = 7.08 Hz), 3.42 (1H, d, J = 16.47 Hz), 3.22-3.18 (2H, m), 3.07 (3H, s), 3.05 (1H, d, J = 16.46 Hz), 2.38-2.24 (2H, m), 2.00-1.42 (2H, m), 1.33 (3H, t, J = 7.14 Hz), 1.26 (3H, t, J = 7.14 Hz). HRMS calcd for C₂₀H₂₈SN₃O₇ (M + H): 454.1648; found: 454.1650.

15


Intermediate 20

2-[2-(1,1-Dioxo-1 λ^6 -[1,2]thiazinan-2-yl)-phenyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester. A solution of 3-[2-(1,1-dioxo-1 λ^6 -[1,2]thiazinan-2-yl)-phenyl]-5-ethoxycarbonylmethyl-2-methyl-2,5-dihydro-[1,2,4]oxadiazole-5-carboxylic acid ethyl ester (3.62 g, 8.0 mmol) in xylenes (50 mL) was refluxed 3 h then cooled to room temperature. The mixture was stored at 5 °C for 5 h. The resulting precipitate was filtered to afford the title product as a pale orange solid (1.67 g, 51% yield). ¹HNMR (300 MHz, CDCl₃) δ : 10.64 (1H, s), 7.65 (1H, dd, J = 8.05, 1.10 Hz), 7.53 (1H, td, J = 7.32, 1.46 Hz), 7.45, (1H, td, J = 7.68, 1.46 Hz), 7.35 (1H, dd, J = 7.32, 1.47 Hz), 4.59-4.49 (1H, m), 4.46-4.35 (1H, m), 3.75 (1H, td, J = 13.17, 2.93 Hz), 3.65-3.58 (1H, m), 3.41 (3H, s), 3.10 (1H, dt, J =

25


12.93, 4.21 Hz), 2.76 (1H, td, $J = 12.45, 4.39$ Hz), 2.36-2.10 (2H, m), 1.77-1.45 (2H, m), 1.38 (3H, t, $J = 7.32$ Hz). HRMS (ESI) calcd for $C_{18}H_{22}N_3O_6S$ ($M + H$): 408.1277; found 408.1231.

5

EXAMPLE 41

N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(2-(1,1-dioxo-1 λ^6 -[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-[2-(1,1-dioxo-1 λ^6 -[1,2]thiazinan-2-yl)-phenyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (0.0814 g, 0.2mmol), and 4-fluorobenzylamine (0.11 mL, 1.0 mmol). The title product was obtained as a lavender solid (0.0626 g, 64% yield). ^1H NMR (300 MHz, CDCl_3) δ : 12.12 (1H, s), 7.83 (1H, bs), 7.64 (1H, d, $J = 7.32$ Hz), 7.54 (1H, td $J = 7.32, 1.46$ Hz), 7.46 (1H, td, $J = 7.69, 1.10$ Hz), 7.33 (1H, d, $J = 7.68$ Hz), 7.28-7.23 (2H, m), 7.00 (2H, t, $J = 8.42$ Hz), 4.59 (1H, dd, $J = 14.83, 6.78$ Hz), 4.46 (1H, dd, $J = 14.82, 6.04$ Hz), 3.68-3.52 (1H, m), 3.44-3.33 (1H, m), 3.38 (3H, m), 3.14-2.94 (1H, m), 2.82-2.73 (1H, m), 2.30-2.06 (2H, m), 1.57-1.52 (1H, m), 1.34-1.19 (1H, m). HRMS (ESI) calcd for $C_{23}H_{22}N_4O_5FS$ ($M-H$): 485.1295; found: 485.1286.


20

EXAMPLE 42

25

N-(3,4-dichlorobenzyl)-5-hydroxy-1-methyl-2-(2-(1,1-Dioxo-1 λ^6 -[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-[2-(1,1-dioxo-1 λ^6 -[1,2]thiazinan-2-yl)-phenyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (0.0814 g, 0.2 mmol) and 3,4-dichlorobenzylamine (0.13 mL, 1.0 mmol). The title product was obtained as white needles after recrystallization from MeOH/H₂O (0.0443 g, 41% yield). ¹HNMR (300 MHz, CDCl₃) δ : 11.98 (1H, s), 7.90 (1H, bs), 7.65 (1H, d, J = 7.68 Hz), 7.55 (1H, td, J = 7.32, 1.46 Hz), 7.47 (1H, td, J = 7.69, 1.46 Hz), 7.40-7.33 (3H, m), 7.13 (1H, dd, J = 8.05, 1.83 Hz), 4.60 (1H, dd, J = 15.18, 6.77 Hz), 4.43 (1H, dd, J = 15.00, 5.86 Hz), 3.62, (1H, bs), 3.49-3.34 (1H, m), 3.38 (3H, s), 3.05 (1H, bs), 2.89-2.75 (1H, m), 2.31-2.09 (2H, m), 1.70-1.54 (2H, m). HRMS (ESI) calcd for C₂₃H₂₃SCl₂N₄O₅ (M+H): 537.0766; found: 537.0758.


15

EXAMPLE 43

N-(3,4-dimethylbenzyl)-5-hydroxy-1-methyl-2-(2-(1,1-Dioxo-1 λ^6 -[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-[2-(1,1-dioxo-1 λ^6 -[1,2]thiazinan-2-yl)-phenyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (0.0814 g, 0.2 mmol) and 3,4-dimethylbenzylamine (0.14 mL, 1.0 mmol). The title product was obtained as lavender needles after recrystallization from MeOH/H₂O (0.0576 g, 58% yield). ¹HNMR (300 MHz, CDCl₃) δ : 12.23 (1H, s), 7.77 (1H, bs), 7.63 (1H, d, J = 7.32 Hz), 7.53 (1H, td, J = 7.31, 1.46 Hz), 7.45 (1H, td, J = 7.68, 0.98 Hz), 7.33 (1H, d, J = 7.32 Hz), 7.08-6.98 (3H, m), 4.55 (1H, dd, J = 14.81, 6.40 Hz), 4.43 (1H, dd, J = 14.64, 5.49 Hz), 3.62


(1H, bs), 3.37 (3H, s), 3.34 (1H, bs), 3.04 (1H, bs), 2.80-2.71 (1H, m), 2.22 (6H, s), 2.22-2.06 (2H, m), 1.64-1.52 (2H, m). HRMS (ESI) calcd for $C_{25}H_{29}SN_4O_5$ (M+H): 497.1859; found: 497.1847.

5

EXAMPLE 44

- N*-(3-chloro-4-methylbenzyl)-5-hydroxy-1-methyl-2-(2-(1,1-dioxo-1 λ^6 -[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-[2-(1,1-dioxo-1 λ^6 -[1,2]thiazinan-2-yl)-phenyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (0.0814 g, 0.2 mmol) and 3-chloro-4-methylbenzylamine (0.14 mL, 1.0 mmol). The title product was obtained as white needles after recrystallization from MeOH/H₂O (0.0416 g, 40% yield). ¹HNMR (300 MHz, CDCl₃) δ : 11.98 (1H, s), 7.84 (1H, bs), 7.64 (1H, d, J = 8.05 Hz), 7.54 (1H, td, J = 7.68, 1.83 Hz), 7.46 (1H, td, J = 7.68, 1.46 Hz), 7.34 (1H, dd, J = 7.32, 1.47 Hz), 7.23 (1H, d, J = 0.74 Hz), 7.17 (1H, d, J = 7.69 Hz), 7.07 (1H, dd, J = 7.69, 1.47 Hz), 4.61 (1H, dd, J = 15.19, 6.77 Hz), 4.40 (1H, dd, J = 15.00, 5.49 Hz), 3.62 (1H, bs), 3.42 (1H, bs) 3.38 (3H, s), 3.05 (1H, bs), 2.83-2.74 (1H, m), 2.33 (3H, s), 2.27-2.11 (2H, m), 1.63-1.60 (2H, m). HRMS (ESI) calcd for $C_{24}H_{26}SClN_4O_5$ (M+H): 517.1312; found: 517.1310.

25


Intermediate 21

N-Hydroxy-N-methyl-2-morpholin-4-yl-benzamidine. To a stirred solution of 2-(4-morpholino)benzonitrile (3.76 g, 20 mmol) and N-methylhydroxylamine hydrochloride (3.34 g, 40.0 mmol) in 1:1 water/ethanol (100 mL) was added sodium carbonate (2.12 g, 20 mmol) and the resulting mixture stirred at 90 °C overnight.


- 5 After cooling and concentrating, the resulting residue was suspended in MeOH/CHCl₃ (1:9). The insoluble solids were removed by filtration and concentration of the mother liquor gave the title product as an amber oil (3.8 g) that was carried on without further purification. LCMS calcd for C₁₂H₁₈N₃O₂ (M + H): 236.13; found: 236.31.

10


Intermediate 22



- 15 *5-Ethoxycarbonylmethyl-2-methyl-3-(2-morpholin-4-yl-phenyl)-2,5-dihydro-[1,2,4]oxadiazole-5-carboxylic acid ethyl ester*. To a stirred solution of N-hydroxy-N-methyl-2-morpholin-4-yl-benzamidine (3.8 g) in ethanol (100 mL, 200 proof) was added diethyl acetylene-dicarboxylate (3.2 mL, 20 mmol) and the resulting mixture stirred at room temperature for 30 min. The mixture was then concentrated and
- 20 purified on a silica gel column (10% -30% ethyl acetate/hexanes) to afford the title compound (3.64 g, 45% yield). ¹HNMR (300 MHz, CDCl₃) δ: 7.64 (1H, dd, J = 7.69, 1.83 Hz), 7.40 (1H, td, J = 8.05, 1.83 Hz), 7.02 (1H, t, J = 7.32 Hz), 6.97 (1H, d, J = 8.05 Hz) 4.31-4.20 (2H, m), 4.15 (2H, q, J = 7.08 Hz), 3.88-3.74 (4H, m), 3.38 (1H, d, J = 16.46 Hz), 3.12-2.92 (4H, m), 3.05 (3H, s), 3.03 (1H, d, J = 16.47 Hz),
- 25 1.29 (3H, t, J = 6.95 Hz), 1.25 (3H, t, J = 6.96 Hz). HRMS (ESI) calcd for C₂₀H₂₈N₃O₆ (M+H): 406.1978; found: 406.1975.

Intermediate 23

5 *5-Hydroxy-1-methyl-2-(2-morpholin-4-yl-phenyl)-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester.* A solution of 5-ethoxycarbonylmethyl-2-methyl-3-(2-morpholin-4-yl-phenyl)-2,5-dihydro-[1,2,4]oxadiazole-5-carboxylic acid ethyl ester (3.64 g, 9.0 mmol) in xylenes (30 mL) was heated to reflux for 18 h then cooled to room temperature. Hexanes (30 mL) was added and the mixture stored at 5
10 °C for 5 h. The solution was decanted leaving a red residue that was purified by silica gel column (25%-50% ethyl acetate/hexanes) to afford the title product as an orange powder (0.4723 g, 14% yield). ¹HNMR (300 MHz, CDCl₃) δ: 10.76 (1H, s), 7.46 (1H, td, J = 8.05, 1.46 Hz), 7.36 (1H, dd, J = 7.68, 1.83 Hz), 7.19 (1H, td, J = 7.32, 0.74 Hz), 7.11 (1H, d, J = 8.06 Hz), 4.58-4.38 (2H, m), 3.63-3.59 (4H, m), 3.36
15 (3H, s), 3.11-3.04 (2H, m), 2.82-2.75 (2H, m), 1.41 (3H, t, J = 7.32 Hz). HRMS (ESI) calcd for C₁₈H₂₂N₃O₅ (M+H): 360.1560; found: 360.1563.

EXAMPLE 45


20

N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(2-morpholinophenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 5-hydroxy-1-methyl-2-(2-morpholin-4-yl-phenyl)-6-oxo-1,6-
25 dihydro-pyrimidine-4-carboxylic acid ethyl ester (0.05 g, 0.15 mmol) and 4-

fluorobenzylamine (0.086 mL, 0.75 mmol). The title product was obtained as a TFA salt, lavender solid (0.0575 g, 87% yield). ^1H NMR (500 MHz, CDCl_3) δ : 12.11 (1H, s), 7.89 (1H, t, $J = 5.49$ Hz), 7.48 (1H, t, $J = 7.63$ Hz), 7.29-7.27 (3H, m), 7.17 (1H, t, $J = 7.63$ Hz), 7.13 (1H, d, $J = 8.24$ Hz), 7.02 (2H, t, $J = 8.55$ Hz), 4.62-4.58, 5 (1H, m), 4.50-4.46 (1H, m), 3.60 (4H, d, $J = 2.75$ Hz), 3.36 (3H, s), 3.01-2.98 (2H, m), 2.78-2.76 (2H, m). HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{24}\text{FN}_4\text{O}_4$ ($\text{M}+\text{H}$): 439.1782; found 439.1767.


EXAMPLE 46

10




N-(3,4-dichlorobenzyl)-5-hydroxy-1-methyl-2-(2-morpholinophenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure 15 described for example 2 from 5-hydroxy-1-methyl-2-(2-morpholin-4-yl-phenyl)-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (0.05 g, 0.15 mmol) and 3,4-dichlorobenzylamine (0.10 mL, 0.75 mmol). The title product was obtained as a TFA salt, lavender foam (0.0461 g, 63% yield). ^1H NMR (500 MHz, CDCl_3) δ : 11.95 (1H, bs), 7.94 (1H, t, $J = 5.50$ Hz), 7.49 (1H, t, $J = 7.63$ Hz), 7.40 (1H, d, $J =$ 20 8.24 Hz), 7.38 (1H, d, $J = 0.91$ Hz), 7.30 (1H, d, $J = 7.33$ Hz), 7.19 (1H, t, $J = 7.33$ Hz), 7.14 (2H, t, $J = 8.09$ Hz), 4.56-4.49 (2H, m), 3.61 (4H, s), 3.36 (3H, s), 2.99 (2H, bs), 2.79 (2H, bs). HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{23}\text{Cl}_2\text{N}_4\text{O}_4$ ($\text{M}+\text{H}$): 489.1096; found: 489.1080.

25

EXAMPLE 47


5 *N*-(3,4-dimethylbenzyl)-5-hydroxy-1-methyl-2-(2-morpholinophenyl)-6-oxo-
1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure
described for example 2 from 5-hydroxy-1-methyl-2-(2-morpholin-4-yl-phenyl)-6-
oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (0.05 g, 0.15 mmol) and
3,4-dimethylbenzylamine (0.11 mL, 0.75 mmol). The title product was obtained as a
10 TFA salt, lavender foam (0.0440 g, 65% yield). ¹HNMR (500 MHz, CDCl₃) δ: 7.84
(1H, t, J = 5.49 Hz), 7.49 (1H, t, J = 7.49 Hz), 7.28 (1H, d, J = 7.63 Hz), 7.18 (1H, t, J
= 7.32 Hz), 7.14 (1H, d, J = 8.24 Hz), 7.09 (1H, d, J = 7.63 Hz), 7.07 (1H, s), 7.03
(1H, d, J = 7.63 Hz), 4.50 (2H, d, J = 5.80 Hz), 3.63 (4H, t, J = 4.57 Hz), 3.37 (3H, s),
2.89 (4H, bs), 2.23 (6H, s). HRMS (ESI) calcd for C₂₅H₂₉N₄O₄ (M+H): 449.2189;
15 found: 449.2182.

EXAMPLE 48

20 *N*-(3-chloro-4-methylbenzyl)-5-hydroxy-1-methyl-2-(2-morpholinophenyl)-6-
oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure
described for example 2 from 5-hydroxy-1-methyl-2-(2-morpholin-4-yl-phenyl)-6-
oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (0.05 g, 0.15 mmol) and 3-
25 chloro-4-methylbenzylamine (0.11 mL, 0.75 mmol). The title product was obtained

as a TFA salt, lavender foam (0.0266 g, 38% yield). ^1H NMR (500 MHz, CDCl_3) δ : 12.07 (1H, bs), 7.88 (1H, t, $J = 6.10$ Hz), 7.48 (1H, td, $J = 6.71, 1.37$ Hz), 7.30-7.27 (2H, m), 7.19-7.16 (2H, m), 7.13 (1H, d, $J = 8.24$ Hz), 7.09 (1H, d, $J = 7.63$ Hz), 4.56-4.53 (1H, m), 4.49-4.45 (m, 1H), 3.61 (4H, d, $J = 4.27$ Hz), 3.36 (3H, s), 3.00 (2H, bs), 2.78 (2H, bs), 2.38 (3H, s). HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{26}\text{ClN}_4\text{O}_4$ ($\text{M}+\text{H}$): 469.1643; found: 469.1628.

Intermediate 24




10

2-Cyano-N,N-dimethyl-benzenesulfonamide. A solution of 2-cyanobenzensulfonylchloride (2.0 g, 10 mmol), dimethyl amine (1.18 g, 10 mmol, 40wt% in water) and triethylamine (1.5 mL, 10 mmol) were stirred together at room temperature for 30 min. The resulting slurry was diluted with ethyl acetate and filtered. The filter cake was washed with ethyl acetate and the combined filtrate was washed with water, dried (Na_2SO_4) and concentrated to give the title product as orange plates (1.78 g, 85% yield). ^1H NMR (300 MHz, CDCl_3) δ : 8.02 (1H, dd, $J = 8.05, 1.46$ Hz), 7.87 (1H, dd, $J = 7.32, 1.47$ Hz), 7.79-7.76 (2H, m), 2.86 (6H, s). LCMS calcd for $\text{C}_9\text{H}_{11}\text{N}_2\text{O}_2\text{S}$ ($\text{M} + \text{H}$): 211.05; found: 211.09.

20


Intermediate 25



25

3-(2-Dimethylsulfamoyl-phenyl)-5-ethoxycarbonylmethyl-2-methyl-2,5-dihydro-[1,2,4]oxadiazole-5-carboxylic acid ethyl ester. To a solution of 2-cyano-N,N-dimethyl-benzenesulfonamide (4.68 g, 22.3 mmol) in ethanol/water (1:1, 150 mL) was added N-methylhydroxylamine hydrochloride (3.72 g, 44.6 mmol) followed by sodium carbonate (2.36 g, 22.3 mmol). The resulting mixture was stirred at 90 °C for 8 h then concentrated. The residue was triturated with MeOH/CHCl₃ (10%) and filtered. The solution was concentrated leaving an orange residue that was dissolved in ethanol (50 mL). Added to this solution was diethyl acetylene-dicarboxylate (3.6 mL, 22.3 mmol) and the resulting mixture stirred at room temp for 30 min. The mixture was concentrated and purified by flash chromatography (25% to 50% EtOAc/Hexanes) to give the title product as a yellow oil (5.57 g, 58% over two steps). ¹HNMR (300 MHz, CDCl₃) δ: 7.93-7.87 (1H, m), 7.66-7.60 (2H, m), 7.56-7.51 (1H, m), 4.39-4.22 (2H, m), 4.16 (q, 2H, J = 7.20 Hz), 3.40 (1H, d, J = 16.47 Hz), 3.15 (1H, d, J = 16.47 Hz), 3.00 (3H, s), 2.82 (6H, s), 1.24 (6H, td, J = 6.95, 1.46 Hz). LCMS calcd for C₁₈H₂₆N₃O₇S (M + H): 428.14; found: 428.10.

Intermediate 26




20

2-(2-Dimethylsulfamoyl-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid ethyl ester. A solution of 3-(2-dimethylsulfamoyl-phenyl)-5-ethoxycarbonylmethyl-2-methyl-2,5-dihydro-[1,2,4]oxadiazole-5-carboxylic acid ethyl ester (5.57g, 13 mmol) in xylenes (50 mL) was stirred at 140 °C for 8 h then cooled to room temperature. Hexanes (30 mL) was added and the mixture was stored at 5 °C for 18 h. The solution was filtered to give the title product as a yellow powder (2.47 g, 50% yield). ¹HNMR (300 MHz, CDCl₃) δ: 10.63 (1H, s), 7.97-7.93 (1H, m), 7.73-7.64 (2H, m), 7.41-7.38 (1H, m), 4.58-4.47 (1H, m), 4.39-

4.28 (1H, m), 3.24 (3H, s), 2.78 (6H, s), 1.32 (3H, t, J = 6.95 Hz). LCMS calcd for $C_{16}H_{20}N_3O_6S$ (M + H): 382.10; found: 382.08.

EXAMPLE 49


5



N-(4-fluorobenzyl)-2-(2-dimethylsulfamoylphenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-(2-dimethylsulfamoyl-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (0.076 g, 0.2mmol), and 4-fluorobenzylamine (0.11 mL, 1.0 mmol). The title product was obtained as white needles (0.0549 g, 60% yield). ^1H NMR (500 MHz, CDCl_3) δ : 12.08 (1H, s), 7.91 (1H, d, J = 7.33 Hz), 7.71-7.66 (3H, m), 7.37 (1H, dd, J = 7.32, 1.83 Hz), 7.22 (2H, q, J = 5.50 Hz), 7.00 (2H, t, J = 8.55 Hz), 4.62 (1H, dd, J = 15.26, 7.02 Hz), 4.40 (1H, dd, J = 14.64, 5.49 Hz), 3.23 (3H, s), 2.64 (6H, s). HRMS (ESI) calcd for $C_{21}H_{22}F\text{N}_4\text{O}_5$ (M+H): 461.1295; found: 461.1300.

20

EXAMPLE 50




N-(3,4-dichlorobenzyl)-2-(2-dimethylsulfamoylphenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-(2-dimethylsulfamoyl-phenyl)-5-hydroxy-1-methyl-


25

6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (0.076 g, 0.2 mmol) and 3,4-dichlorobenzylamine (0.13 mL, 1.0 mmol). The title product was obtained as white needles (0.0569 g, 56% yield). ¹HNMR (500 MHz, CDCl₃) δ: 11.93 (1H, s), 7.91 (1H, dd, J = 7.32 Hz), 7.74 (1H, t, J = 5.80 Hz), 7.72-7.67 (2H, m), 7.38 (2H, d, J = 7.93 Hz), 7.32 (1H, d, J = 1.83 Hz), 7.11 (1H, dd, J = 8.24, 1.83 Hz), 4.60 (1H, dd, J = 15.26, 7.02 Hz), 4.41 (1H, dd, J = 15.26, 5.80 Hz), 3.24 (3H, s), 2.69 (6H, s). HRMS (ESI) calcd for C₂₁H₂₁SCl₂N₄O₅ (M+H): 511.0610; found: 511.0612.

EXAMPLE 51





N-(3,4-dimethylbenzyl)-2-(2-dimethylsulfamoylphenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-(2-dimethylsulfamoyl-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (0.076 g, 0.2 mmol) and 3,4-dimethylbenzylamine (0.14 mL, 1.0 mmol). The title product was obtained as white needles (0.0560 g, 60% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.19 (1H, s), 7.91 (1H, dd, J = 7.48, 1.68 Hz), 7.71-7.65 (2H, m), 7.61 (1H, m), 7.36 (1H, dd, J = 7.48, 1.68 Hz), 7.07 (1H, d, J = 7.33 Hz), 7.00 (1H, s), 6.96 (1H, d, J = 7.63 Hz), 4.57 (1H, dd, J = 14.65, 7.02 Hz), 4.37 (1H, dd, J = 14.65 Hz), 3.23 (3H, s), 2.63 (6H, s), 2.22 (6H, s). HRMS (ESI) calcd for C₂₃H₂₇SN₄O₅ (M + H): 471.1702; found 471.1708.



EXAMPLE 52




5 *N*-(3-chloro-4-methylbenzyl)-2-(2-dimethylsulfonylphenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide. Prepared according to the procedure described for example 2 from 2-(2-dimethylsulfonyl-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid ethyl ester (0.076 g, 0.2 mmol) and 3-chloro-4-methylbenzylamine (0.14 mL, 1.0 mmol). The title product
10 was obtained as white needles (0.0601 g, 61% yield). ¹HNMR (500 MHz, CDCl₃) δ: 12.05 (1H, s), 7.92 (1H, dd, J = 7.47, 1.83 Hz), 7.72-7.66 (3H, m), 7.38 (1H, dd, J = 7.17, 2.29 Hz), 7.19 (1H, s), 7.16 (1H, d, J = 7.63 Hz), 7.04 (1H, d, J = 7.63 Hz), 4.61 (1H, dd, J = 14.95, 7.02 Hz), 4.36 (1H, dd, J = 14.96, 5.19 Hz), 3.24 (3H, s), 2.66 (6H, s), 2.32 (3H, s). HRMS (ESI) calcd for C₂₂H₂₄ClN₄O₅S (M + H): 491.1156;
15 found: 491.1159.




EXAMPLES 53-105




Examples 53-105 were prepared according to the procedures described for
20 examples 1-52.





Example	Structure	Name and Analytical data
53		<p>N-(4-fluorobenzyl)-5-hydroxy-2-(3-[2-(1,1-Dioxo-1λ⁶-[1,2]thiazinan-2-yl)-pyridin-2-yl]-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ¹HNMR (500 MHz, CDCl₃) δ: 12.31 (1H, br s), 8.64 (1H, dd, J = 4.6, 1.5 Hz), 7.97 (1H, dd, J = 8.2, 1.2 Hz), 7.50 (1H, dd, J = 8.2, 4.9 Hz), 7.26 (2H, dd, J = 8.8, 5.2 Hz), 7.00 (2H, t, J = 8.6 Hz), 4.53 (2H, d, J = 4.6 Hz), 3.54-3.45 (2H, m), 3.41 (3H, s), 2.96-2.88 (2H, m), 2.21-2.15 (2H, m), 1.53-1.44 (2H, m). HRMS calcd for C₂₂H₂₃FN₅O₅S (M + H): 488.1404; found: 488.1395. Anal. Cald for C₂₂H₂₂FN₅O₅S •0.25 CF₃CO₂H: C, 52.37; H, 4.35; N, 13.57; found: C, 52.47; H, 4.56; N, 13.46.</p>
54		<p>N-(3,4-dichlorobenzyl)-5-hydroxy-2-(3-[2-(1,1-Dioxo-1λ⁶-[1,2]thiazinan-2-yl)-pyridin-2-yl]-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ¹HNMR (500 MHz, CDCl₃) δ: 12.05 (1H, s), 8.64 (1H, dd, J = 4.9, 1.5 Hz), 7.97 (1H, dd, J = 8.2, 1.5 Hz), 7.49 (1H, dd, J = 8.2, 4.9 Hz), 7.39 (1H, d, J = 8.2 Hz), 7.37 (1H, J = 1.8 Hz), 7.14 (1H, dd, J = 8.2, 1.8 Hz), 4.52 (2H, d, J = 4.9 Hz), 3.55-3.48 (2H, m), 3.42 (3H, s), 3.00-2.94 (2H, m), 2.25-2.20 (2H, m), 1.61-1.54 (2H, m). HRMS calcd for C₂₂H₂₂Cl₂N₅O₅S (M + H): 538.0719; found: 538.0717.</p>






55		<p>N-(3,4-dimethylbenzyl)-5-hydroxy-2-(3-[2-(1,1-Dioxo-1λ⁶-[1,2]thiazinan-2-yl)-pyridin-2-yl]-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ¹HNMR (500 MHz, CDCl₃) δ: 12.27 (1H, s), 8.63 (1H, dd, J = 4.6, 1.2 Hz), 7.95 (1H, dd, J = 8.2, 1.2 Hz), 7.75 (1H, br s), 7.48 (1H, dd, J = 8.2, 4.6 Hz), 7.06 (1H, d, J = 7.6 Hz), 7.03 (1H, d, J = 1.5 Hz), 6.99 (1H, dd, J = 7.6, 1.5 Hz), 4.49 (2H, d, J = 4.3 Hz), 3.54-3.47 (2H, m), 3.41 (3H, s), 2.93-2.88 (2H, m), 2.22 (6H, s), 2.19-2.14 (2H, m), 1.49-1.44 (2H, m). HRMS calcd for C₂₄H₂₈N₅O₅S (M + H): 498.1811; found: 498.1820.</p>
56		<p>N-(3-chloro-4-methylbenzyl)-5-hydroxy-2-(3-[2-(1,1-Dioxo-1λ⁶-[1,2]thiazinan-2-yl)-pyridin-2-yl]-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ¹HNMR (500 MHz, CDCl₃) δ: 8.59 (1H, dd, J = 4.6, 1.2 Hz), 7.93 (1H, dd, J = 8.2, 1.2 Hz), 7.47 (1H, dd, J = 8.2, 4.6 Hz), 7.20 (1H, d, J = 1.2 Hz), 7.13 (1H, d, J = 7.6 Hz), 7.03 (1H, dd, J = 7.6, 1.2 Hz), 4.48-4.43 (2H, br s), 3.53-3.46 (2H, m), 3.36 (3H, s), 3.34-3.33 (2H, m), 2.94-2.88 (2H, m), 2.28 (3H, s), 2.18-2.13 (2H, m), 1.53-1.44 (2H, m). HRMS calcd for C₂₃H₂₅ClN₅O₅S (M + H): 518.1265; found: 518.1272.</p>




57		<p>N-(4-fluorobenzyl)-5-hydroxy-2-(6-methoxypyridin-3-yl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, MeOD) δ: 8.44 (1H, s), 7.94 (1H, d, $J = 8.5$ Hz), 7.38 (2H, dd, $J = 5.6, 2.1$ Hz), 7.05 (2H, t, $J = 8.5$ Hz), 6.93 (1H, d, $J = 8.5$ Hz), 4.54 (2H, s), 4.00 (3H, s), 3.52 (3H, s). HRMS (M+H) calcd for $\text{C}_{19}\text{H}_{18}\text{FN}_4\text{O}_4$: 385.13122; found: 385.1312.</p>
58		<p>N-(3,4-dichlorobenzyl)-5-hydroxy-2-(6-methoxypyridin-3-yl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, MeOD) δ: 8.45 (1H, s), 7.95 (1H, d, $J = 7.3$ Hz), 7.53 (1H, s), 7.48 (1H, d, $J = 7.9$ Hz), 7.31 (1H, d, $J = 8.2$ Hz), 6.93 (1H, d, $J = 8.5$ Hz), 4.54 (2H, s), 4.00 (3H, s), 3.52 (3H, s). HRMS (M+H) calcd for $\text{C}_{19}\text{H}_{17}\text{Cl}_2\text{N}_4\text{O}_4$: 435.0627; found: 435.0617.</p>
59		<p>N-(3,4-dimethylbenzyl)-5-hydroxy-2-(6-methoxypyridin-3-yl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, MeOD) δ: 8.43 (1H, s), 7.93 (1H, d, $J = 8.2$ Hz), 7.12 (1H, s), 7.09-7.05 (2H, m), 6.92 (1H, d, $J = 8.2$ Hz), 4.49 (2H, s), 4.00 (3H, s), 3.52 (3H, s), 2.25 (3H, s), 2.24 (3H, s). HRMS (M+H) calcd for $\text{C}_{21}\text{H}_{23}\text{N}_4\text{O}_4$: 395.17194; found: 395.1718.</p>




60		<p>N-(4-fluorobenzyl)-5-hydroxy-2-(3-methoxypyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1HNMR (500 MHz, CDCl_3) δ: 12.25 (1H, br s), 8.32 (1H, d, $J = 4.6$ Hz), 7.85 (1H, s), 7.47 (1H, dd, $J = 8.5, 4.6$ Hz), 7.39 (1H, d, $J = 8.2$ Hz), 7.27 (2H, dd, $J = 8.5, 5.2$ Hz), 6.99 (2H, t, $J = 8.5$ Hz), 4.52 (2H, d, $J = 6.1$ Hz), 3.86 (3H, s), 3.32 (3H, s). HRMS calcd for $\text{C}_{19}\text{H}_{18}\text{N}_4\text{O}_4$ ($\text{M} + \text{H}$): 385.1312; found: 385.1316.</p>
61		<p>N-(4-fluorobenzyl)-2-(3-(dimethylamino)pyridin-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, CDCl_3) δ: 8.36 (1H, s), 8.18 (1H, bs), 7.69 (1H, d, $J = 8.5$ Hz), 7.66-7.64 (1H, m), 7.31 (2H, dd, $J = 8.4, 5.3$ Hz), 6.99 (2H, t, $J = 8.7$ Hz), 4.54 (2H, d, $J = 4.9$ Hz), 3.53 (3H, s), 2.81 (6H, s). HRMS ($\text{M} + \text{H}$) calcd for $\text{C}_{20}\text{H}_{21}\text{FN}_5\text{O}_3$: 398.16285; found: 398.1626.</p>
62		<p>N-(3,4-dichlorobenzyl)-2-(3-(dimethylamino)pyridin-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, CDCl_3) δ: 8.37 (2H, bs), 7.85 (1H, d, $J = 8.5$ Hz), 7.79 (1H, d, $J = 7.3$ Hz), 7.43 (1H, s), 7.38 (1H, d, $J = 8.2$ Hz), 7.19 (1H, d, $J = 8.2$ Hz), 4.52 (2H, s), 3.38 (3H, s), 2.88 (6H, s). HRMS ($\text{M} + \text{H}$) calcd for $\text{C}_{20}\text{H}_{20}\text{Cl}_2\text{N}_5\text{O}_3$: 448.09433; found: 448.0938.</p>




63		<p>N-(3,4-dimethylbenzyl)-2-(3-(dimethylamino)pyridin-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, CDCl_3) δ: 8.30 (1H, s), 8.07 (1H, bs), 7.52-7.46 (2H, m), 7.09-7.04 (3H, m), 4.50 (2H, d, $J = 5.5$ Hz), 3.34 (3H, s), 2.74 (6H, s), 2.22 (3H, s), 2.21 (3H, s). HRMS ($M+H$) calcd for $\text{C}_{22}\text{H}_{26}\text{N}_5\text{O}_3$: 408.20357; found: 408.2035.</p>
64		<p>N-(3-chloro-4-methylbenzyl)-2-(3-(dimethylamino)pyridin-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, CDCl_3) δ: 8.37 (1H, s), 8.20 (1H, bs), 7.67-7.62 (2H, m), 7.31 (1H, s), 7.17-7.13 (2H, m), 4.51 (2H, s), 3.36 (3H, s), 2.81 (6H, s), 2.32 (3H, s). HRMS ($M+H$) calcd for $\text{C}_{21}\text{H}_{23}\text{ClN}_5\text{O}_3$: 428.14895; found: 428.1485.</p>
65		<p>N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-phenyl-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, CDCl_3) δ: 12.14 (1H, br s), 7.91 (1H, br s), 7.52-7.47 (3H, m), 7.43-7.41 (2H, m), 7.29-7.26 (2H, m), 7.03-7.00 (2H, m), 4.55 (2H, d, $J = 6.4$ Hz), 3.45 (3H, s). HRMS calcd for $\text{C}_{19}\text{H}_{17}\text{FN}_3\text{O}_3$ ($M + H$): 354.1254; found: 354.1253.</p>




66		<p>N-(3,4-dichlorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-phenyl-1,6-dihydropyrimidine-4-carboxamide: ^1HNMR (500 MHz, CDCl_3) δ: 11.99 (1H, br s), 7.95 (1H, br s), 7.53-7.48 (3H, m), 7.44-7.39 (4H, m), 7.16-7.14 (1H, m), 4.53 (2H, d, $J = 6.4$ Hz), 3.45 (3H, s). HRMS calcd for $\text{C}_{19}\text{H}_{16}\text{Cl}_2\text{N}_3\text{O}_3$ ($M + H$): 404.0569; found: 404.0570.</p>
67		<p>N-(3,4-dimethylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-phenyl-1,6-dihydropyrimidine-4-carboxamide: ^1HNMR (500 MHz, CDCl_3) δ: 12.25 (1H, s), 7.86 (1H, br s), 7.51-7.46 (3H, m), 7.42-7.40 (2H, m), 7.10-7.02 (3H, m), 4.51 (2H, d, $J = 6.1$ Hz), 3.45 (3H, s), 2.23 (3H, s), 2.22 (3H, s). HRMS calcd for $\text{C}_{21}\text{H}_{22}\text{N}_3\text{O}_3$ ($M + H$): 364.1661; found: 364.1662.</p>
68		<p>N-(3-chloro-4-methylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-phenyl-1,6-dihydropyrimidine-4-carboxamide: ^1HNMR (500 MHz, CDCl_3) δ: 12.13 (1H, s), 7.90 (1H, br s), 7.52-7.47 (3H, m), 7.44-7.41 (2H, m), 7.28-7.27 (1H, m), 7.19-7.17 (1H, m), 7.10-7.08 (1H, m), 4.52 (2H, d, $J = 6.4$ Hz), 3.45 (3H, s), 2.33 (3H, s). HRMS calcd for $\text{C}_{20}\text{H}_{19}\text{ClN}_3\text{O}_3$ ($M + H$): 384.1115; found: 384.1124.</p>
69		<p>N-(4-fluorobenzyl)-5-hydroxy-2-(3-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: HRMS calcd for $\text{C}_{20}\text{H}_{19}\text{FN}_3\text{O}_4$ ($M + H$): 384.1360; found: 384.1359.</p>




70		N-(3,4-dichlorobenzyl)-5-hydroxy-2-(3-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: HRMS calcd for $C_{20}H_{18}Cl_2N_3O_4$ (M + H): 434.0675; found: 434.0667.
71		N-(3,4-dimethylbenzyl)-5-hydroxy-2-(3-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: HRMS calcd for $C_{22}H_{24}N_3O_4$ (M + H): 394.1767; found: 394.1774.
72		N-(4-fluorobenzyl)-5-hydroxy-2-(4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: HRMS calcd for $C_{20}H_{19}FN_3O_4$ (M + H): 384.1360; found: 384.1362.
73		N-(3,4-dichlorobenzyl)-5-hydroxy-2-(4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: HRMS calcd for $C_{20}H_{18}Cl_2N_3O_4$ (M + H): 434.0675; found: 434.0671.
74		N-(3,4-dimethylbenzyl)-5-hydroxy-2-(4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: HRMS calcd for $C_{22}H_{24}N_3O_4$ (M + H): 394.1767; found: 394.1767.




75		<p>N-(4-fluorobenzyl)-5-hydroxy-2-[2-(2-hydroxyethylamino)phenyl]-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylate: ^1H NMR (500 MHz, CDCl_3) δ: 8.16 (1H, s), 7.43 (1H, t, $J = 7.5$ Hz), 7.30 (2H, dd, $J = 7.9, 2.4$ Hz), 7.12 (1H, d, $J = 7.3$ Hz), 7.01-6.94 (4H, m), 4.51 (2H, d, $J = 5.5$ Hz), 3.90 (2H, s), 3.42-3.36 (6H, m). HRMS ($\text{M}+\text{H}$) calcd for $\text{C}_{21}\text{H}_{22}\text{FN}_4\text{O}_4$: 413.16252; found: 413.1636.</p>
76		<p>N-(3,4-dichlorobenzyl)-5-hydroxy-2-(2-(2-hydroxyethylamino)phenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, CDCl_3) δ: 8.34 (1H, bs), 7.47 (1H, t, $J = 7.3$ Hz), 7.42 (1H, s), 7.36 (1H, d, $J = 8.4$ Hz), 7.19-7.15 (2H, m), 7.09 (1H, d, $J = 7.9$ Hz), 7.04 (1H, t, $J = 7.5$ Hz), 4.46 (2H, d, $J = 5.5$ Hz), 3.92 (2H, s), 3.43 (6H, s). ($\text{M}+\text{H}$) calcd for $\text{C}_{21}\text{H}_{21}\text{Cl}_2\text{N}_4\text{O}_4$: 463.0940; found: 463.0943.</p>
77		<p>N-(4-fluorobenzyl)-2-(2-(bis(2-hydroxyethyl)amino)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, CDCl_3) δ: 8.17 (1H, t, $J = 6.0$ Hz), 7.42 (1H, d, $J = 1.5$ Hz), 7.40-7.37 (2H, m), 7.16 (1H, dd, $J = 8.1, 1.6$ Hz), 7.10 (1H, d, $J = 8.7$ Hz), 6.98 (1H, t, $J = 8.7$ Hz), 6.89-6.86 (2H, m), 4.46 (2H, d, $J = 6.4$ Hz), 3.88 (2H, s), 3.63 (2H, bs), 3.54 (2H, bs), 3.43 (3H, s), 3.37-3.35 (4H, m). HRMS ($\text{M}+\text{H}$) calcd for $\text{C}_{23}\text{H}_{26}\text{FN}_4\text{O}_5$: 457.18873; found: 457.1890.</p>




78		<p>2-(4-((4-fluorobenzyl)carbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)benzoic acid: ^1H NMR (500 MHz, CDCl_3) δ: 12.14 (1H, bs), 8.20 (1H, d, $J = 7.3$ Hz), 7.79 (1H, s), 7.71 (1H, t, $J = 7.3$ Hz), 7.63 (1H, t, $J = 7.5$ Hz), 7.35 (1H, d, $J = 7.3$ Hz), 7.04-6.97 (3H, m), 4.50 (2H, s), 3.24 (3H, s). HRMS ($\text{M}+\text{H}$) calcd for $\text{C}_{20}\text{H}_{17}\text{FN}_3\text{O}_5$: 398.11523; found: 398.1147.</p>
79		<p>2-(4-((3,4-dichlorobenzyl)carbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)benzoic acid: ^1H NMR (500 MHz, CDCl_3) δ: 12.00 (1H, bs), 8.20 (1H, d, $J = 7.6$ Hz), 7.83 (1H, s), 7.73 (1H, t, $J = 7.5$ Hz), 7.64 (1H, t, $J = 7.3$ Hz), 7.36 (3H, d, $J = 7.6$ Hz), 7.13 (1H, d, $J = 7.9$ Hz), 4.48 (2H, s), 3.25 (3H, s). HRMS ($\text{M}+\text{H}$) calcd for $\text{C}_{20}\text{H}_{16}\text{Cl}_2\text{N}_3\text{O}_5$: 448.04671; found: 448.0466.</p>
79		<p>N-(4-fluorobenzyl)-2-(2-(dimethylamino)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, CDCl_3) δ: 10.68 (1H, bs), 7.78 (1H, t, $J = 5.0$ Hz), 7.64 (1H, t, $J = 7.5$ Hz), 7.49 (1H, d, $J = 8.24$ Hz), 7.44-7.41 (2H, m), 7.29-7.26 (2H, m), 7.00 (2H, t, $J = 8.5$ Hz), 4.53 (2H, d, $J = 5.8$ Hz), 3.33 (3H, s), 3.03 (6H, s). HRMS ($\text{M}+\text{H}$) calcd for $\text{C}_{21}\text{H}_{22}\text{FN}_4\text{O}_3$: 397.1676; found: 397.1677.</p>




80		<p>N-(3,4-dichlorobenzyl)-2-(2-(dimethylamino)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, CDCl_3) δ: 11.94 (1H, bs), 8.01 (1H, s), 7.43 (1H, t, $J = 7.3$ Hz), 7.40-7.38 (2H, m), 7.26 (1H, d, $J = 7.6$ Hz), 7.16 (1H, dd, $J = 8.1, 1.7$ Hz), 7.10-7.06 (2H, m), 4.52 (2H, s), 3.31 (3H, s), 2.64 (6H, s). HRMS ($\text{M}+\text{H}$) calcd for $\text{C}_{21}\text{H}_{21}\text{Cl}_2\text{N}_4\text{O}_3$: 447.09908; found: 447.0990.</p>
81		<p>N-(3,4-dimethylbenzyl)-2-(2-(dimethylamino)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, CDCl_3) δ: 12.20 (1H, s), 7.42 (1H, t, $J = 7.2$ Hz), 7.23 (1H, d, $J = 7.3$ Hz), 7.10-7.03 (5H, m), 4.50 (2H, d, $J = 11.0$ Hz), 3.31 (3H, s), 2.63 (6H, s), 2.23 (6H, s). HRMS ($\text{M}+\text{H}$) calcd for $\text{C}_{23}\text{H}_{27}\text{N}_4\text{O}_3$: 407.20833; found: 407.2088.</p>
82		<p>N-(3-chloro-4-methylbenzyl)-2-(2-(dimethylamino)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, CDCl_3) δ: 12.06 (1H, s), 7.95 (1H, s), 7.42 (1H, t, $J = 7.5$ Hz), 7.28-7.25 (2H, m), 7.17 (1H, d, $J = 7.9$ Hz), 7.10-7.04 (3H, m), 4.51 (2H, d, $J = 19.8$ Hz), 3.31 (3H, s), 2.63 (6H, s), 2.33 (3H, s). HRMS ($\text{M}+\text{H}$) calcd for $\text{C}_{22}\text{H}_{24}\text{ClN}_4\text{O}_3$: 427.1537; found: 427.1540.</p>




83		<p>N-(4-fluorobenzyl)-2-(furan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, MeOD) δ: 7.69 (1H, s), 7.44 (2H, td, $J = 5.3, 2.4$ Hz), 7.40 (2H, td, $J = 5.5, 2.7$ Hz), 7.14 (2H, t, $J = 8.5$ Hz), 7.08 – 7.04 (3H, m), 6.61 (1H, dd, $J = 1.18, 1.5$ Hz), 4.59 (2H, s), 4.02 (2H, s), 3.61 (3H, s).</p> <p>HRMS (M+H) calcd for $\text{C}_{17}\text{H}_{15}\text{FN}_3\text{O}_4$: 344.10467; found: 344.1059.</p>
84		<p>N-(3,4-dichlorobenzyl)-2-(furan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, MeOD) δ: 7.79 (1H, s), 7.55 (1H, s), 7.50 (1H, d, $J = 8.2$ Hz), 7.32 (1H, d, $J = 7.9$ Hz), 7.28 (1H, s), 6.68 (1H, s), 4.57 (2H, s), 3.75 (3H, s). HRMS (M+H) calcd for $\text{C}_{17}\text{H}_{14}\text{Cl}_2\text{N}_3\text{O}_4$: 394.03615; found: 394.0358.</p>
86		<p>N-(3,4-dimethylbenzyl)-2-(furan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, MeOD) δ: 7.77 (1H, s), 7.25 (1H, d, $J = 3.1$ Hz), 7.14 (1H, s), 7.11 – 7.06 (2H, m), 6.66 (1H, dd, $J = 1.8, 1.5$ Hz), 4.52 (2H, s), 3.74 (3H, s), 2.26 (3H, s), 2.25 (3H, s). HRMS (M+H) calcd for $\text{C}_{19}\text{H}_{20}\text{N}_3\text{O}_4$: 354.14539; found: 354.1462.</p>




87		<p>N-(3-chloro-4-methylbenzyl)-2-(furan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, MeOD) δ: 7.78 (1H, s), 7.37 (1H, s), 7.28 – 7.25 (2H, m), 7.21 (1H, d, $J = 7.63$ Hz), 6.67 (1H, s), 4.53 (2H, s), 3.75 (3H, s), 2.35 (3H, s). HRMS (M+H) calcd for $\text{C}_{18}\text{H}_{17}\text{ClN}_3\text{O}_4$: 374.09077; found: 374.0913.</p>
88		<p>N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-3-yl)-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (300 MHz, CDCl_3) δ: 11.35 (1H, bs), 9.23 (1H, s), 8.99 (1H, d, $J = 5.1$ Hz), 8.47 (1H, d, $J = 7.7$ Hz), 8.00 (1H, dd, $J = 8.0, 2.6$ Hz), 7.87 (1H, t, $J = 5.8$ Hz), 7.28 (2H, dd, $J = 8.8, 3.3$ Hz), 7.00 (2H, t, $J = 8.6$ Hz), 4.56 (2H, d, $J = 6.2$ Hz), 3.55 (3H, s). HRMS (M+H) calcd for $\text{C}_{18}\text{H}_{16}\text{FN}_4\text{O}_3$: 355.12065; found: 355.1207.</p>
89		<p>N-(3,4-dichlorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-3-yl)-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, CDCl_3) δ: 13.02 (1H, bs), 8.95 (1H, s), 8.82 (1H, s), 8.10 (1H, s), 7.91 (1H, s), 7.71 (1H, s), 7.43-7.38 (2H, m), 7.17-7.13 (1H, m), 4.55 (2H, s), 3.51 (3H, s). HRMS (M+H) calcd for $\text{C}_{18}\text{H}_{15}\text{Cl}_2\text{N}_4\text{O}_3$: 405.05213; found: 405.0514.</p>


90		<p>N-(3,4-dimethylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-3-yl)-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, CDCl_3) δ: 12.39 (1H, bs), 8.96 (1H, s), 8.86 (1H, s), 8.17 (1H, d, $J=7.3$ Hz), 7.77 (2H, s), 7.13-7.00 (3H, m), 4.52 (2H, d, $J=4.0$ Hz), 3.51 (3H, s), 2.23 (3H, s), 2.22 (3H, s). HRMS ($M+H$) calcd for $\text{C}_{20}\text{H}_{21}\text{N}_4\text{O}_3$: 365.16138; found: 365.1612.</p>
91		<p>N-(3-chloro-4-methylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-3-yl)-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, CDCl_3) δ: 12.37 (1H, bs), 9.01 (1H, s), 8.87 (1H, s), 8.23 (1H, d, $J=6.7$ Hz), 7.85 (1H, s), 7.80 (1H, s), 7.26 (1H, s), 7.17 (1H, d, $J=7.6$ Hz), 7.10 (1H, d, $J=8.8$ Hz), 4.52 (2H, s), 3.51 (3H, s), 2.32 (3H, s). HRMS ($M+H$) calcd for $\text{C}_{19}\text{H}_{18}\text{ClN}_4\text{O}_3$: 385.10675; found: 385.1064.</p>
92		<p>N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-4-yl)-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, DMSO) δ: 12.61 (1H, bs), 9.42 (1H, t, $J=6.4$ Hz), 8.81 (2H, d, $J=6.1$ Hz), 7.77 (2H, d, $J=6.1$ Hz), 7.37-7.34 (2H, m), 7.16-7.13 (2H, m), 4.44 (2H, d, $J=6.41$ Hz), 3.32 (3H, s). HRMS ($M+H$) calcd for $\text{C}_{18}\text{H}_{16}\text{FN}_4\text{O}_3$: 355.12065; found: 355.1206.</p>

93		<p>N-(3,4-dichlorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-4-yl)-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, CDCl_3) δ: 12.18 (1H, s), 8.79 (2H, d, $J = 4.3$ Hz), 7.90 (1H, bs), 7.42-7.39 (4H, m), 7.16 (1H, d, $J = 7.9$ Hz), 4.54 (2H, d, $J = 6.1$ Hz), 3.46 (3H, s). HRMS ($\text{M}+\text{H}$) calcd for $\text{C}_{18}\text{H}_{15}\text{Cl}_2\text{N}_4\text{O}_3$: 405.05213; found: 405.0540.</p>
94		<p>N-(3,4-dimethylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-4-yl)-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, CDCl_3) δ: 13.30 (1H, bs), 8.90 (2H, d, $J = 4.9$ Hz), 7.73 (2H, d, $J = 5.2$ Hz), 7.68 (1H, s), 7.11-7.02 (3H, m), 4.52 (2H, d, $J = 5.8$ Hz), 3.48 (3H, s), 2.23 (6H, s). HRMS ($\text{M}+\text{H}$) calcd for $\text{C}_{20}\text{H}_{21}\text{N}_4\text{O}_3$: 365.16138; found: 365.1610.</p>
95		<p>N-(3-chloro-4-methylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-4-yl)-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, CDCl_3) δ: 12.30 (1H, s), 8.79 (2H, d, $J = 4.6$ Hz), 7.83 (1H, bs), 7.41 (2H, d, $J = 4.9$ Hz), 7.28 (1H, s), 7.18 (1H, d, $J = 7.6$ Hz), 7.10 (1H, d, $J = 7.6$ Hz), 4.53 (2H, d, $J = 6.1$ Hz), 3.46 (3H, s), 2.33 (3H, s). HRMS ($\text{M}+\text{H}$) calcd for $\text{C}_{19}\text{H}_{18}\text{ClN}_4\text{O}_3$: 385.10675; found: 385.1071.</p>

96		<p>N-(4-fluorobenzyl)-2-(1,5-dimethyl-1H-pyrrol-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (300 MHz, CDCl_3) δ: 12.04 (1H, s), 7.87 (1H, t, $J = 5.8$ Hz), 7.30-7.25 (2H, m), 7.02 (2H, t, $J = 8.6$ Hz), 6.29 (1H, d, $J = 3.7$ Hz), 5.98 (1H, dd, $J = 3.7, 0.7$ Hz), 4.55 (2H, d, $J = 6.2$ Hz), 3.56 (3H, s), 3.46 (3H, s), 2.26 (3H, s). HRMS ($\text{M}+\text{H}$) calcd for $\text{C}_{19}\text{H}_{20}\text{FN}_4\text{O}_3$: 371.15195; found: 371.1511.</p>
97		<p>N-(3,4-dichlorobenzyl)-2-(1,5-dimethyl-1H-pyrrol-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (300 MHz, CDCl_3) δ: 11.90 (1H, s), 7.93 (1H, t, $J = 6.0$ Hz), 7.42-7.39 (2H, m), 7.15 (2H, dd, $J = 8.4, 2.2$ Hz), 6.30 (1H, d, $J = 4.0$ Hz), 5.99 (1H, dd, $J = 3.7, 0.7$ Hz), 4.53 (2H, d, $J = 6.6$ Hz), 3.56 (3H, s), 3.48 (3H, s), 2.27 (3H, s). HRMS ($\text{M}+\text{H}$) calcd for $\text{C}_{19}\text{H}_{19}\text{Cl}_2\text{N}_4\text{O}_3$: 421.08343; found: 421.0840.</p>
98		<p>N-(3,4-dimethylbenzyl)-2-(1,5-dimethyl-1H-pyrrol-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, CDCl_3) δ: 12.15 (1H, s), 7.83 (1H, d, $J = 5.0$ Hz), 7.09 (1H, d, $J = 7.6$ Hz), 7.07 (1H, s), 7.03 (1H, d, $J = 1.9$ Hz), 6.29 (1H, d, $J = 3.7$ Hz), 5.97 (1H, d, $J = 3.7$ Hz), 4.50 (2H, d, $J = 6.1$ Hz), 3.56 (3H, s), 3.46 (3H, s), 2.26 (3H, s), 2.24 (6H, s). HRMS ($\text{M}+\text{H}$) calcd for $\text{C}_{21}\text{H}_{25}\text{N}_4\text{O}_3$: 381.19268; found: 381.1929.</p>

99		<p>N-(3-chloro-4-methylbenzyl)-2-(1,5-dimethyl-1H-pyrrol-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (500 MHz, CDCl_3) δ: 12.00 (1H, bs), 7.87 (1H, t, $J = 5.8$ Hz), 7.27 (1H, d, $J = 1.5$ Hz), 7.19 (1H, d, $J = 7.6$ Hz), 7.09 (1H, dd, $J = 7.9, 1.5$ Hz), 6.29 (1H, d, $J = 3.7$ Hz), 5.98 (1H, dd, $J = 3.7, 0.9$ Hz), 4.52 (2H, d, $J = 6.4$ Hz), 3.57 (3H, s), 3.48 (3H, s), 2.34 (3H, s), 2.27 (3H, s). HRMS ($\text{M}+\text{H}$) calcd for $\text{C}_{20}\text{H}_{22}\text{ClN}_4\text{O}_3$: 401.13805; found: 401.1381.</p>
100		<p>N-(4-fluorobenzyl)-2-(2,4-dimethylimidazo[1,5-a]pyrimidin-8-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (300 MHz, CDCl_3) δ: 8.35 (1H, bs), 8.24 (1H, s), 7.31 (2H, dd, $J = 8.4, 5.3$ Hz), 6.99 (2H, t, $J = 8.7$ Hz), 6.58 (1H, s), 4.57 (2H, d, $J = 6.4$ Hz), 3.80 (3H, s), 2.67 (3H, s), 2.46 (3H, s). HRMS ($\text{M}+\text{H}$) calcd for $\text{C}_{21}\text{H}_{20}\text{FN}_6\text{O}_3$: 423.1581; found: 423.1575.</p>
101		<p>N-(3,4-dichlorobenzyl)-2-(2,4-dimethylimidazo[1,5-a]pyrimidin-8-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (300 MHz, CDCl_3) δ: 8.58 (1H, bs), 8.53 (1H, s), 7.42 (1H, s), 7.37 (1H, d, $J = 8.2$ Hz), 7.19 (1H, dd, $J = 8.2, 1.5$ Hz), 6.68 (1H, s), 4.55 (2H, d, $J = 6.4$ Hz), 3.82 (3H, s), 2.71 (3H, s), 2.56 (3H, s). HRMS ($\text{M}+\text{H}$) calcd for $\text{C}_{21}\text{H}_{19}\text{Cl}_2\text{N}_6\text{O}_3$: 473.08958; found: 473.0902.</p>

102		<p>N-(3,4-dimethylbenzyl)-2-(2,4-dimethylimidazo[1,5-a]pyrimidin-8-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (300 MHz, CDCl_3) δ: 12.09 (1H, bs), 8.22 (1H, bs), 8.11 (1H, s), 7.10 (1H, s), 7.06 (2H, s), 6.52 (1H, s), 4.52 (2H, d, J = 6.1 Hz), 3.79 (3H, s), 2.65 (3H, s), 2.40 (3H, s), 2.22 (3H, s), 2.21 (3H, s). HRMS ($M+H$) calcd for $\text{C}_{23}\text{H}_{25}\text{N}_6\text{O}_3$: 433.19882; found: 433.1996.</p>
103		<p>N-(3-chloro-4-methylbenzyl)-2-(2,4-dimethylimidazo[1,5-a]pyrimidin-8-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide: ^1H NMR (300 MHz, CDCl_3) δ: 8.52 (1H, s), 8.49 (1H, bs), 7.30 (1H, s), 7.14 (2H, dd, J = 15.0, 7.9 Hz), 6.66 (1H, s), 4.53 (2H, d, J = 5.8 Hz), 3.82 (3H, s), 2.71 (3H, s), 2.55 (3H, s), 2.31 (3H, s). HRMS ($M+H$) calcd for $\text{C}_{22}\text{H}_{22}\text{ClN}_6\text{O}_3$: 453.1442; found: 453.1447.</p>
104		<p>2-(4-methylaminicarbonyl-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid 4-fluorobenzylamide: ^1H NMR (500 MHz, acetone-d_6) δ 12.41 (1H, s), 9.44 (1H, br.s), 9.05 (1H, br.s), 7.79 (2H, d, J = 8.5 Hz), 7.55 (2H, d, J = 8.5 Hz), 7.09 (2H, m), 7.44 (2H, m), 4.62 (2H, d, J = 6.5 Hz), 3.44 (3H, s), 2.14 (3H, s). HRMS calcd for $\text{C}_{21}\text{H}_{18}\text{FN}_4\text{O}_4$ ($M - H$): 409.1312; found: 409.1317. Anal. Calcd for $\text{C}_{21}\text{H}_{19}\text{FN}_4\text{O}_4 \cdot \text{H}_2\text{O}$: C, 58.81; H, 4.94; N, 13.08; found: C, 58.88; H, 5.40; N, 13.23.</p>

105		<p>N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-p-tolyl-1,6-dihydropyrimidine-4-carboxamide:</p> <p>¹H NMR (300 MHz, CDCl₃) δppm 2.42 (3H, s), 3.45 (3H, s), 4.54 (2H, d, J = 6.3 Hz), 7.00 (2H, m), 7.3 (6H, m), 7.92 (1H, br). HRMS (M+H) calcd for C₂₀H₁₉FN₃O₃: 368.1410, found 368.1400.</p>
-----	---	---

EXAMPLE 106

HIV-Integrase Inhibition Activity


- 5 To evaluate *in-vitro* activity against HIV-integrase, 5 pmole of biotin labeled substrate DNA was bound to 100 µg of Streptavidin coated PVT SPA beads (Amersham Pharmacia Biotech). Recombinant integrase (0.26 ng) was incubated with the beads for 90 min at 37 °C. Unbound enzyme was removed by washing the complex followed by addition of inhibitors and 0.1 fmol of P33 labeled target DNA.
- 10 The reaction was stopped by adding EDTA to a final concentration of 10 mM. Samples were counted in TopCountNXT (Packard) and the CPM was used as a measure of integration. The reaction condition was as described in A. Engelman and R. Craigie, *J. Virol.* 69, 5908-5911 (1995). The sequences of substrate and target DNA were described in *Nucleic Acid Research* 22, 1121-1122 (1994). Using this
- 15 assay, examples 1-98 were found to have an IC₅₀ = 0.002 to 2 µM.

Although the invention has been described with respect to specific aspects, those skilled in the art will recognize that other aspects not specifically described herein are intended to be within the scope of the claims which follow.

CLAIMS

We claim:

1. A compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof,




wherein

10

A is methylene or 1,1-disubstituted ethylene;

B is selected from the group consisting of



R^1 is phenyl, pyridinyl or dioxolanylphenyl and is unsubstituted or substituted with 1 to 3 R^3 ;

20 R^2 is hydrogen, methyl, or OR^4 ;

R^3 is independently selected from halo, C_{1-6} alkyl, C_{1-2} perfluoroalkyl, C_{1-6} alkoxy, C_{1-6} alkylthioxy, and cyano;

25 R^4 is hydrogen or C_{1-6} alkyl;

R^5 is Ar^1 or Ar^2 ;

R⁶ is C₁₋₆alkyl;

Ar¹ is phenyl substituted with 1-2 substituents selected from halo, C₁₋₆alkoxy, CO₂R⁴, N(R⁴)(SO₂C₁₋₆alkyl), SO₂N(C₁₋₆alkyl)₂, and dioxothiazinanyl;

5

Ar² is a heteroaryl moiety selected from the group consisting of pyridinyl, pyrrolyl, furanyl, and imidazopyrimidinyl and is unsubstituted or substituted with 1-2 substituents selected from halo, C₁₋₆alkyl, C₁₋₆alkoxy, CO₂R⁴, N(R⁴)(SO₂C₁₋₆alkyl), SO₂N(C₁₋₆alkyl)₂, N(R⁷)₂, and dioxothiazinanyl; and

10

R⁷ is hydrogen, C₁₋₆alkyl, C₁₋₆alkylOR⁴.

2. A compound of claim 1 wherein R¹ is phenyl unsubstituted or substituted with 1 to 3 R³.

15

3. A compound of claim 2 where R¹ is phenyl substituted with 1-2 R³ selected from the group consisting of chloro, fluoro, methyl, and trifluoromethyl.

4. A compound of claim 1 where R² is hydrogen.

20

5. A compound of claim 1 where R⁵ is Ar¹.

6. A compound of claim 5 where Ar¹ is phenyl substituted with 1-2 R³ selected from the group consisting of chloro, fluoro, methoxy, N(Me)SO₂Me, SO₂N(Me)₂, SO₂Me, and dioxothiazinanyl.

25

7. A compound of claim 5 selected from the group consisting of

N-(4-fluorobenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

30

N-(3,4-dichlorobenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

- N-(3,4-difluorobenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- 5 N-(4-chlorobenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- N-(4-methylbenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- 10 N-(3,4-dimethylbenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- N-(3-chloro-4-methylbenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- 15 N-(2,4-difluorobenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- N-(2-methylbenzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- 20 N-(4-fluoro-2-(trifluoromethyl)benzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- 25 N-(4-(trifluoromethyl)benzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- N-(benzo[d][1,3]dioxol-5-ylmethyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- 30 2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-N-(1-phenylethyl)-1,6-dihydropyrimidine-4-carboxamide;

N-(2-(methylthio)benzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

5 N-(3-fluoro-4-(trifluoromethyl)benzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3,5-bis(trifluoromethyl)benzyl)-2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

10 2-(2,6-difluorophenyl)-5-hydroxy-1-methyl-6-oxo-N-(pyridin-2-ylmethyl)-1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-dichlorobenzyl)-5-hydroxy-2-(2-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

15

N-(4-fluorobenzyl)-5-hydroxy-2-(2-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

20 N-(3,4-dimethylbenzyl)-5-hydroxy-2-(2-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3-chloro-4-methylbenzyl)-5-hydroxy-2-(2-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

25 N-(4-fluorobenzyl)-2-(4-fluoro-2-(methylsulfonyl)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-dichlorobenzyl)-2-(4-fluoro-2-(methylsulfonyl)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

30

N-(3,4-dimethylbenzyl)-2-(4-fluoro-2-(methylsulfonyl)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(4-fluorobenzyl)-2-(2-fluoro-6-(N-methylmethan-3-ylsulfonamido)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

5 N-(3,4-dichlorobenzyl)-2-(2-fluoro-6-(N-methylmethan-3-ylsulfonamido)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

10 N-(3-chloro-4-methylbenzyl)-2-(2-fluoro-6-(N-methylmethan-3-ylsulfonamido)phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(4-fluorobenzyl)-2-(2,6-dimethoxyphenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

15 N-(3,4-dichlorobenzyl)-2-(2,6-dimethoxyphenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-dimethylbenzyl)-2-(2,6-dimethoxyphenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

20 N-(3-chloro-4-methylbenzyl)-2-(2,6-dimethoxyphenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

25 N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(2-(1,1-Dioxo-1 λ^6 -[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-dichlorobenzyl)-5-hydroxy-1-methyl-2-(2-(1,1-Dioxo-1 λ^6 -[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

30 N-(3,4-dimethylbenzyl)-5-hydroxy-1-methyl-2-(2-(1,1-Dioxo-1 λ^6 -[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3-chloro-4-methylbenzyl)-5-hydroxy-1-methyl-2-(2-(1,1-Dioxo-1 λ ⁶-
[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

5 N-(3-chloro-4-methylbenzyl)-5-hydroxy-1-methyl-2-(2-morpholinophenyl)-6-oxo-
1,6-dihydropyrimidine-4-carboxamide;

N-(4-fluorobenzyl)-2-(2-dimethylsulfamoylphenyl)-5-hydroxy-1-methyl-6-oxo-1,6-
dihydropyrimidine-4-carboxamide;

10 N-(3,4-dichlorobenzyl)-2-(2-dimethylsulfamoylphenyl)-5-hydroxy-1-methyl-6-oxo-
1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-dimethylbenzyl)-2-(2-dimethylsulfamoylphenyl)-5-hydroxy-1-methyl-6-oxo-
1,6-dihydropyrimidine-4-carboxamide;

15 N-(3-chloro-4-methylbenzyl)-2-(2-dimethylsulfamoylphenyl)-5-hydroxy-1-methyl-6-
oxo-1,6-dihydropyrimidine-4-carboxamide;

20 N-(4-fluorobenzyl)-5-hydroxy-2-(3-methoxyphenyl)-1-methyl-6-oxo-1,6-
dihydropyrimidine-4-carboxamide;

N-(3,4-dichlorobenzyl)-5-hydroxy-2-(3-methoxyphenyl)-1-methyl-6-oxo-1,6-
dihydropyrimidine-4-carboxamide;

25 N-(3,4-dimethylbenzyl)-5-hydroxy-2-(3-methoxyphenyl)-1-methyl-6-oxo-1,6-
dihydropyrimidine-4-carboxamide;

N-(4-fluorobenzyl)-5-hydroxy-2-(4-methoxyphenyl)-1-methyl-6-oxo-1,6-
dihydropyrimidine-4-carboxamide;

30 N-(3,4-dichlorobenzyl)-5-hydroxy-2-(4-methoxyphenyl)-1-methyl-6-oxo-1,6-
dihydropyrimidine-4-carboxamide;

N-(3,4-dimethylbenzyl)-5-hydroxy-2-(4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

2-(4-((4-fluorobenzyl)carbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)benzoic acid;

2-(4-((3,4-dichlorobenzyl)carbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)benzoic acid; and

2-(4-methylaminicarbonyl-phenyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid 4-fluorobenzylamide; and

or a pharmaceutically acceptable salt or solvate thereof.

8. A compound of claim 1 where R^5 is Ar^2 .

9. A compound of claim 8 where Ar^2 is substituted with 1-2 substituents selected from the group consisting of chloro, fluoro, methyl, methoxy, dimethylamino, 2-hydroxyethylamino, di(2-hydroxyethyl)amino, $N(Me)SO_2Me$, $SO_2N(Me)_2$, SO_2Me , and dioxothiazinanyl.

10. A compound of claim 8 selected from the group consisting of

N-(4-chlorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-2-yl)-1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-dichlorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-2-yl)-1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-difluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-2-yl)-1,6-dihydropyrimidine-4-carboxamide;

- N-(4-methylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-2-yl)-1,6-dihydropyrimidine-4-carboxamide;
- 5 N-(3,4-dimethylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-2-yl)-1,6-dihydropyrimidine-4-carboxamide;
- N-(3-chloro-4-methylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-2-yl)-1,6-dihydropyrimidine-4-carboxamide;
- 10 N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-2-yl)-1,6-dihydropyrimidine-4-carboxamide;
- N-(4-fluorobenzyl)-5-hydroxy-2-(3-[2-(1,1-Dioxo-1 λ ⁶-[1,2]thiazinan-2-yl)-pyridin-2-yl]-)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- 15 N-(3,4-dichlorobenzyl)-5-hydroxy-2-(3-[2-(1,1-Dioxo-1 λ ⁶-[1,2]thiazinan-2-yl)-pyridin-2-yl]-)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- N-(3,4-dimethylbenzyl)-5-hydroxy-2-(3-[2-(1,1-Dioxo-1 λ ⁶-[1,2]thiazinan-2-yl)-pyridin-2-yl]-)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- 20 N-(3-chloro-4-methylbenzyl)-5-hydroxy-2-(3-[2-(1,1-Dioxo-1 λ ⁶-[1,2]thiazinan-2-yl)-pyridin-2-yl]-)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- N-(4-fluorobenzyl)-5-hydroxy-2-(6-methoxypyridin-3-yl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- 25 N-(3,4-dichlorobenzyl)-5-hydroxy-2-(6-methoxypyridin-3-yl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;
- 30 N-(3,4-dimethylbenzyl)-5-hydroxy-2-(6-methoxypyridin-3-yl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(4-fluorobenzyl)-5-hydroxy-2-(3-methoxypyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

5 N-(4-fluorobenzyl)-2-(3-(dimethylamino)pyridin-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-dichlorobenzyl)-2-(3-(dimethylamino)pyridin-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

10 N-(3,4-dimethylbenzyl)-2-(3-(dimethylamino)pyridin-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3-chloro-4-methylbenzyl)-2-(3-(dimethylamino)pyridin-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

15

N-(4-fluorobenzyl)-2-(furan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

20 N-(3,4-dichlorobenzyl)-2-(furan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-dimethylbenzyl)-2-(furan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

25 N-(3-chloro-4-methylbenzyl)-2-(furan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-3-yl)-1,6-dihydropyrimidine-4-carboxamide;

30

N-(3,4-dichlorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-3-yl)-1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-dimethylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-3-yl)-1,6-dihydropyrimidine-4-carboxamide;

5 N-(3-chloro-4-methylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-3-yl)-1,6-dihydropyrimidine-4-carboxamide;

N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-4-yl)-1,6-dihydropyrimidine-4-carboxamide;

10 N-(3,4-dichlorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-4-yl)-1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-dimethylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-4-yl)-1,6-dihydropyrimidine-4-carboxamide;

15

N-(3-chloro-4-methylbenzyl)-5-hydroxy-1-methyl-6-oxo-2-(pyridin-4-yl)-1,6-dihydropyrimidine-4-carboxamide;

20 N-(4-fluorobenzyl)-2-(1,5-dimethyl-1H-pyrrol-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-dichlorobenzyl)-2-(1,5-dimethyl-1H-pyrrol-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

25 N-(3,4-dimethylbenzyl)-2-(1,5-dimethyl-1H-pyrrol-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3-chloro-4-methylbenzyl)-2-(1,5-dimethyl-1H-pyrrol-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

30

N-(4-fluorobenzyl)-2-(2,4-dimethylimidazo[1,5-a]pyrimidin-8-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

N-(3,4-dichlorobenzyl)-2-(2,4-dimethylimidazo[1,5-a]pyrimidin-8-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

5 N-(3,4-methylbenzyl)-2-(2,4-dimethylimidazo[1,5-a]pyrimidin-8-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide; and

N-(3-chloro-4-methylbenzyl)-2-(2,4-dimethylimidazo[1,5-a]pyrimidin-8-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;

10 or a pharmaceutically acceptable salt or solvate thereof.

11. A compound of claim 1 where R⁶ is methyl.

12. A composition useful for treating HIV infections comprising a therapeutic
15 amount of a compound of claim 1, or a salt or solvate thereof, and a pharmaceutically acceptable carrier.

13. A method of inhibiting HIV integrase which comprises
administering to a patient a therapeutically effective amount of a compound of Claim
20 1, or a pharmaceutically acceptable salt or solvate thereof.

14. A method of treating HIV infection in a patient comprising the administration
of a therapeutically effective amount of a compound of Claim 1, or a
pharmaceutically acceptable salt or solvate thereof.

25

15. A method of treating HIV infection in a patient comprising administering a
therapeutically effective amount of a compound of claim 1 with at least one other
agent for treating HIV selected from the group consisting of HIV reverse
transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV
protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5
30 inhibitors, CXCR4 inhibitors, HIV budding or maturation inhibitors, and HIV
integrase inhibitors.

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
11 November 2004 (11.11.2004)

PCT

(10) International Publication Number
WO 2004/096128 A3

(51) International Patent Classification⁷: **C07D 401/04**,
401/06, 403/06, 403/12, 413/04, 409/04, A61K 31/513,
31/5377, A61D 31/541

GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2004/011759

(22) International Filing Date: 16 April 2004 (16.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/465,176 24 April 2003 (24.04.2003) US

(71) Applicant (for all designated States except US): **BRIS-
TOL-MYERS SQUIBB COMPANY** [US/US]; Route
206 and Province Line Road, Princeton, NJ 08543-4000
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **NAIDU, B.**
Narasimhulu [IN/US]; 12 Skeetfield Point Rd., Durham,
CT 06422 (US). **WALKER, Michael, A.** [US/US]; 76R
Ivy Way, Durham, CT 06422 (US). **SORENSEN, Mar-
garet, E.** [US/US]; 27 Harrison Street, Apt. 13, Meriden,
CT 06450 (US).

(74) Agents: **EPPERSON, James et al.**; Bristol-Myers Squibb
Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD,
SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT,
LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG)

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for the following desig-
nations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW,
BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ,
EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,
IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA,
ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ,
SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG)


Published:

— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
10 March 2005

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: HIV INTEGRASE INHIBITORS



(57) Abstract: The present invention relates to a series of
pyrimidine compounds of Formula (I) which inhibit HIV
integrase and to pharmaceutical compositions and methods of
treatment for AIDS or ARC using these compounds.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/11759

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07D 401/04, 401/06, 403/04, 403/12, 413/04, 409/04; A61K 31/513, 31/5377, 31/541
US CL : 544/3, 281, 319; 514/222.2, 259.1, 269

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 544/3, 281, 319; 514/222.2, 259.1, 269

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 03/035076 A1 (ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA) 01 May 2003, see formula (I).	1-15

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

10 December 2004 (10.12.2004)

Date of mailing of the international search report

04 JAN 2005

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner of Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Deepak Rao

Telephone No. 571-272-1600